[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1174
1. Papageorgiou KI, Kaniorou-Larai MG: A case report of Merkel cell carcinoma on chronic lymphocytic leukemia: differential diagnosis of coexisting lymphadenopathy and indications for early aggressive treatment. BMC Cancer; 2005;5:106
MedlinePlus Health Information. consumer health - Lymphatic Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of Merkel cell carcinoma on chronic lymphocytic leukemia: differential diagnosis of coexisting lymphadenopathy and indications for early aggressive treatment.
  • BACKGROUND: Chronic lymphocytic leukemia (CLL) is a monoclonal disorder, characterized by a progressive proliferation of functionally incompetent B lymphocytes.
  • There is increased evidence of association between CLL and skin cancers, including the uncommon Merkel cell carcinoma (MCC).
  • During the recurrences of MCC, coexisting regional lymphadenopathy, posed a problem in the differential diagnosis and treatment of lymph node involvement.
  • Histopathology and immunoistochemistry showed that submandibular lymphadenopathy coexisting with the second recurrence of MCC, was due to B-cell small lymphocytic lymphoma.
  • The subsequent and more aggressive recurrence of the skin tumor had involved the superficial and deep cervical lymph nodes.
  • CONCLUSION: MCC has a high incidence of regional lymphadenopathy at presentation (12-45%) and even when it arises on the background of chronic leukemia, lymphadenopathy at presentation should be managed agressively with elective lymph node dissection.
  • We overview the postulated correlation between Merkel tumor and CCL, the differential diagnosis of regional lymphadenopathy during the recurrences of the skin tumor and the strategies of treatment.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphatic Diseases / diagnosis
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Lip Neoplasms / metabolism. Lip Neoplasms / pathology. Lymphatic Metastasis. Male. Neoplasm Metastasis. Recurrence. Skin Neoplasms / complications. Skin Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1978 Nov;42(5):2311-21 [719609.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):588-98 [11786590.001]
  • [Cites] Differentiation. 1984;28(2):136-54 [6084624.001]
  • [Cites] Am J Surg Pathol. 1985 Feb;9(2):95-108 [2579594.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):178-82 [3940617.001]
  • [Cites] J Invest Dermatol. 1986 Jan;86(1):74-7 [2427595.001]
  • [Cites] Cancer. 1987 Dec 15;60(12):2958-64 [3499971.001]
  • [Cites] Am J Ophthalmol. 1992 Jun 15;113(6):674-80 [1598958.001]
  • [Cites] Arch Surg. 1991 Dec;126(12):1514-9 [1842182.001]
  • [Cites] J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):143-56 [8335732.001]
  • [Cites] J Clin Oncol. 1994 Sep;12(9):1974-90 [8083719.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Ann Surg Oncol. 1997 Jul-Aug;4(5):389-95 [9259965.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):881-5 [9307187.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Dermatol Surg. 1999 Jan;25(1):23-5 [9935088.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):153-8 [10067813.001]
  • [Cites] Arch Surg. 1999 Apr;134(4):388-92; discussion 392-3 [10199311.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):107-14 [10561025.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):22-9 [10687725.001]
  • [Cites] Br J Dermatol. 2000 Mar;142(3):525-8 [10735964.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1842-51 [10760761.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Feb;127(2):149-54 [11177031.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1358-62 [11283937.001]
  • [Cites] Arch Otolaryngol. 1984 Nov;110(11):707-12 [6487123.001]
  • (PMID = 16111484.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1208865
  •  go-up   go-down


2. Jia F, Figueroa SD, Gallazzi F, Balaji BS, Hannink M, Lever SZ, Hoffman TJ, Lewis MR: Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates. J Nucl Med; 2008 Mar;49(3):430-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular imaging of bcl-2 expression in small lymphocytic lymphoma using 111In-labeled PNA-peptide conjugates.
  • The bcl-2 gene is overexpressed in non-Hodgkin's lymphoma (NHL), such as small lymphocytic lymphoma (SLL), and many other cancers.
  • In vitro studies were performed in Mec-1 SLL cells, which express both bcl-2 messenger RNA and somatostatin receptors.
  • Biodistributions and microSPECT/CT studies were performed in Mec-1-bearing SCID (severe combined immunodeficiency) mice, a new animal model of human SLL.
  • CONCLUSION: A new (111)In-labeled antisense PNA-peptide conjugate demonstrated proof of principle for molecular imaging of bcl-2 expression in a new mouse model of human SLL.
  • [MeSH-major] Indium Radioisotopes / pharmacokinetics. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / radionuclide imaging. Peptide Nucleic Acids / pharmacokinetics. Proto-Oncogene Proteins c-bcl-2 / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Isotope Labeling. Metabolic Clearance Rate. Mice. Mice, SCID. Molecular Probe Techniques. Organ Specificity. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287262.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 103130
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indium Radioisotopes; 0 / Peptide Nucleic Acids; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Radiopharmaceuticals
  •  go-up   go-down


3. Saxena A, Memauri B, Hasegawa W: Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour. J Clin Pathol; 2005 Mar;58(3):331-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial diagnosis of small lymphocytic lymphoma in parotidectomy for Warthin tumour, a rare collision tumour.
  • Warthin tumours (WT) and malignant lymphomas are only rarely associated, and most are examples of involvement of the lymphoid stroma of WT by a disseminated lymphoma.
  • This report describes a case where excision of a parotid mass led to the initial diagnosis of WT and small lymphocytic lymphoma (SLL).
  • The diagnosis of SLL was confirmed by immunohistochemistry and molecular studies.
  • This case highlights the extremely rare association of SLL with WT and the importance of evaluation of the WT stroma, where the pale proliferation centres of SLL may mimic germinal centres of reactive lymphoid nodules.
  • [MeSH-major] Adenolymphoma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Jan;113(1):113-9 [10631864.001]
  • [Cites] Histopathology. 1993 Mar;22(3):280-1 [8495960.001]
  • [Cites] Ear Nose Throat J. 1979 Aug;58(8):345-50 [583035.001]
  • [Cites] Pathol Annu. 1979;14 Pt 2:307-24 [583554.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(1):13-38 [7467121.001]
  • [Cites] Cancer. 1982 Dec 15;50(12):2948-50 [7139585.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1088-92 [6692300.001]
  • [Cites] Hum Pathol. 1985 Apr;16(4):424-7 [3980011.001]
  • [Cites] J Pathol. 1985 Jul;146(3):167-77 [3928854.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;408(5):491-6 [3082065.001]
  • [Cites] Pathol Res Pract. 1986 Oct;181(5):615-20 [3786253.001]
  • [Cites] Am J Clin Pathol. 1989 Mar;91(3):341-4 [2538052.001]
  • [Cites] Tumori. 1990 Apr 30;76(2):212-5 [2184550.001]
  • [Cites] Hum Pathol. 1990 Sep;21(9):974-7 [2394439.001]
  • [Cites] Pathology. 1992 Apr;24(2):60-2 [1322520.001]
  • [Cites] Ear Nose Throat J. 1993 Apr;72(4):264-9, 272-3 [8486105.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]
  • (PMID = 15735173.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770608
  •  go-up   go-down


Advertisement
4. M'Hidi H, Thibult ML, Chetaille B, Rey F, Bouadallah R, Nicollas R, Olive D, Xerri L: High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Clin Pathol; 2009 Oct;132(4):589-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
  • B- and T-lymphocyte attenuator (BTLA) is a lymphoid receptor that inhibits lymphocyte activation on interaction with its ligand, herpesvirus entry mediator (HVEM).
  • In reactive lymph nodes, they were both expressed in interfollicular T cells and in B cells from mantle and marginal zones.
  • BTLA was strongly expressed in chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL, 19 of 19 positive) when compared with other small B-cell lymphomas, including follicular lymphoma (0 of 24 positive), mantle cell lymphoma (0 of 10 positive), and marginal zone lymphoma (0 of 5 positive).
  • Our results suggest that down-regulation of the BTLA-HVEM pathway may be involved in germinal center B-cell activation.
  • The specific high expression of BTLA in B-CLL/SLL represents a new potential diagnostic tool.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Receptors, Immunologic / biosynthesis. Receptors, Tumor Necrosis Factor, Member 14 / biosynthesis. T-Lymphocytes, Helper-Inducer / immunology
  • [MeSH-minor] Animals. B-Lymphocytes / immunology. Down-Regulation. Humans. Immunohistochemistry. Mice

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19762537.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BTLA protein, human; 0 / Receptors, Immunologic; 0 / Receptors, Tumor Necrosis Factor, Member 14; 0 / TNFRSF14 protein, human
  •  go-up   go-down


5. Türköz HK, Polat N, Akin I, Ozcan D: Micronodular T-cell/histiocyte-rich B-cell lymphoma of the spleen in a case of small lymphocytic lymphoma: a Richter's transformation. Ups J Med Sci; 2010 Aug;115(3):217-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronodular T-cell/histiocyte-rich B-cell lymphoma of the spleen in a case of small lymphocytic lymphoma: a Richter's transformation.
  • Abstract A case of micronodular T-cell/histiocyte-rich B-cell lymphoma of the spleen who had a prior diagnosis of small lymphocytic lymphoma is presented.
  • Micronodular T-cell/histiocyte-rich B-cell lymphoma of the spleen was first described in 2003, and very few cases have been reported since then.
  • This is the first reported case supervening in a patient with pre-existing chronic lymphocytic lymphoma.
  • We review its clinical, pathologic, and immunohistochemical features and the difficulties we encountered during diagnosis.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Splenic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1268-76 [11688461.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):895-902 [12826881.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Ann Diagn Pathol. 2008 Aug;12(4):290-2 [18620998.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1302-8 [7023653.001]
  • [Cites] Nouv Rev Fr Hematol. 1964 May-Jun;4:456-7 [14186230.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):128-32 [16330953.001]
  • [Cites] Int J Surg Pathol. 2004 Jan;12(1):31-7 [14765270.001]
  • (PMID = 20218944.001).
  • [ISSN] 2000-1967
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2939524
  •  go-up   go-down


6. Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, Arnoulet C, Olive D: Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol; 2008 Jul;39(7):1050-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
  • PD-1 expression was recently reported in some T-cell non-Hodgkin lymphoma (NHL) subtypes, but the expression profile of PD-1 and its ligands (PD-L1 and PD-L2) in B-NHLs remains largely to be characterized.
  • A series of 161 lymphoma tissue and 11 blood samples was analyzed using either immunohistochemistry or flow cytometry.
  • In reactive lymph nodes, PD-1 was mainly expressed in follicular T cells.
  • In B-NHLs, PD-1 was mainly expressed in reactive T cells; but expression was also noted in neoplastic B cells from small lymphocytic lymphoma (SLL, 12/13), grade III follicular lymphoma (3/3), and diffuse large cell lymphoma (2/25).
  • In contrast, neoplastic B cells from mantle cell lymphoma (0/11), marginal zone lymphoma (0/12), Burkitt lymphoma (0/3), and grade 1 to 2 follicular lymphoma (0/40) were PD-1 negative.
  • PD-L1 and PD-L2 were negative in small B-cell lymphomas, including B-SLL.
  • Flow cytometry showed that blood cells from chronic lymphocytic leukemia (B-CLL) also displayed PD-1 expression, which could be increased by CD40 stimulation.
  • These results show that PD-1 expression among B-NHLs is mainly associated with SLL/CLL and is influenced by activation of the CD40/CD40L pathway.
  • Because the anti-PD-1.6.4 antibody works on paraffin sections, it represents a useful tool to differentiate SLL/CLL from other small B-cell lymphomas.
  • [MeSH-major] Antigens, CD / metabolism. Apoptosis Regulatory Proteins / metabolism. Biomarkers, Tumor / metabolism. Immunoblastic Lymphadenopathy / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Animals. Diagnosis, Differential. Flow Cytometry. Lymph Nodes / metabolism. Lymph Nodes / pathology. Mice. Mice, Inbred BALB C. Programmed Cell Death 1 Receptor

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Hum Pathol. 2010 Nov;41(11):1655. Seriari, Nacer [corrected to Serriari, Nacer]
  • (PMID = 18479731.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


7. Khaled S, Gotlieb V, Schuster IP, Saif MW: Multiple lymphomatous polyposis associated with small lymphocytic lymphoma: a unique presentation. J Gastrointestin Liver Dis; 2008 Dec;17(4):461-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple lymphomatous polyposis associated with small lymphocytic lymphoma: a unique presentation.
  • Multiple lymphomatous polyposis (MLP) is a rare extra-nodal manifestation of lymphoma.
  • In most cases, MLP is associated with mantle cell lymphoma (MCL).
  • We report a 66-year-old male diagnosed with small lymphocytic lymphoma (SLL)/chronic lymphocytic lymphoma (CLL), who showed evidence of rectal bleeding.
  • A CT-scan of the abdomen and pelvis showed an enlarged spleen, multiple paraaortic and mesenteric lymph nodes, and some diverticular pouching along the antimesenteric border of the pelvic colon.
  • A colonoscopy revealed the presence of multiple polypoid lesions, biopsies of which showed diffuse lymphoid infiltrate without any identifiable follicles.
  • Immunohistochemical analysis combined with a Fluorescence In-Situ Hybridization (FISH) study excluded the diagnosis of MCL.
  • A bone marrow aspiration biopsy demonstrated diffuse infiltration of the bone marrow with low grade lymphocytes that expressed CD 20, CD5 and CD23, with negative BCL-1, t (11;.
  • A diagnosis of B-cell CLL with kappa light chain restriction was made.
  • Multiple lymphomatous polyposis is considered to be a digestive counterpart to MCL and can therefore be considered as a presentation of MCL.
  • The patient's bone marrow revealed a B-cell lymphoma of CLL/SLL phenotype, which to our knowledge has not been linked to MLP in previously reported cases.
  • [MeSH-major] Colonic Polyps / diagnosis. Colorectal Neoplasms / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, Mantle-Cell / diagnosis
  • [MeSH-minor] Aged. B-Lymphocytes / metabolism. Biomarkers, Tumor / metabolism. Bone Marrow / pathology. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104711.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Giordano A, Perrone T, Guarini A, Ciappetta P, Rubini G, Ricco R, Palma M, Specchia G, Liso V: Primary intracranial dural B cell small lymphocytic lymphoma. Leuk Lymphoma; 2007 Jul;48(7):1437-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intracranial dural B cell small lymphocytic lymphoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Meningeal Neoplasms / diagnosis
  • [MeSH-minor] Adult. Dura Mater / pathology. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / pathology. Magnetic Resonance Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613779.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


9. Matsushita K, Nagahama K, Inayama Y, Fujimaki K, Tamura K, Hirawa N, Kihara M, Toya Y, Yabana M, Joh K, Umemura S: Lobular membranoproliferative glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits associated with B cell small lymphocytic lymphoma. Nephrol Dial Transplant; 2005 Jun;20(6):1273-4
Hazardous Substances Data Bank. C.I. DIRECT RED 28 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular membranoproliferative glomerulonephritis with organized microtubular monoclonal immunoglobulin deposits associated with B cell small lymphocytic lymphoma.
  • [MeSH-major] Glomerulonephritis / epidemiology. Glomerulonephritis / pathology. Immunoglobulin G / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Paraproteinemias / metabolism

  • Genetic Alliance. consumer health - Glomerulonephritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840665.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Immunoglobulin kappa-Chains; 3U05FHG59S / Congo Red
  •  go-up   go-down


10. Kurtin PJ: Indolent lymphomas of mature B lymphocytes. Hematol Oncol Clin North Am; 2009 Aug;23(4):769-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indolent lymphomas of mature B lymphocytes.
  • The lymphomas of small B lymphocytes are a biologically diverse group of B cell derived neoplasms that includes B cell small lymphocytic lymphoma/chronic lymphocytic leukemia; mantle cell lymphoma; follicular lymphoma; nodal, splenic and extranodal marginal zone lymphomas; and lymphoplasmacytic lymphoma.
  • This article reviews the essential diagnostic and biologic features of these clinically indolent B cell malignancies.
  • [MeSH-major] Lymphoma, B-Cell / classification. Lymphoma, B-Cell / diagnosis
  • [MeSH-minor] Chromosome Aberrations. Diagnosis, Differential. Humans. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Waldenstrom Macroglobulinemia / diagnosis. Waldenstrom Macroglobulinemia / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577169.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 72
  •  go-up   go-down


11. Vlachaki E, Tselios K, Charalambidou S, Ioannidou E, Klonizakis I: Pure red cell aplasia complicating B cell small lymphocytic lymphoma: a case report. Int J Hematol; 2008 Oct;88(3):341-2
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure red cell aplasia complicating B cell small lymphocytic lymphoma: a case report.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Red-Cell Aplasia, Pure / complications

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2005 Oct;58(10):1118-20 [16189165.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1021-8 [17640861.001]
  • [Cites] Hematology. 2007 Jun;12(3):245-8 [17558701.001]
  • [Cites] Rinsho Ketsueki. 2007 Jan;48(1):67-70 [17313080.001]
  • [Cites] Leuk Res. 2006 Jan;30(1):109-14 [16043218.001]
  • [Cites] Am J Hematol. 2007 Sep;82(9):812-4 [17546635.001]
  • (PMID = 18766306.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


12. Campidelli C, Sabattini E, Piccioli M, Rossi M, De Blasi D, Miraglia E, Rodriguez-Abreu D, Franscini LL, Bertoni F, Mazzucchelli L, Cavalli F, Zucca E, Pileri SA: Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. Hum Pathol; 2007 May;38(5):787-92
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases.
  • We report on 2 composite lymphomas occurring in elderly patients, morphologically characterized by the combination of peripheral T-cell lymphoma (PTCL) unspecified and B-cell small lymphocytic lymphoma.
  • Immunohistochemistry provided objective confirmation of the coexistence of the 2 malignancies, as did molecular biology by revealing clonal T-cell receptor gamma and immunoglobulin heavy chain gene rearrangements.
  • One of the patients had no history of indolent lymphoma either at the personal and family level, whereas the other showed a strong familial predisposition, his mother and sister having suffered from B-cell chronic lymphocytic leukemia.
  • To the best of our knowledge, the simultaneous occurrence of PTCL unspecified and B-cell small lymphocytic lymphoma is an exceptional event; the possible pathogenetic correlations between the 2 neoplasms are discussed.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Lymphoma, B-Cell / complications. Lymphoma, T-Cell, Peripheral / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270243.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


13. Ameen R, Sajnani KP, Albassami A, Refaat S: Frequencies of non-Hodgkin's lymphoma subtypes in Kuwait: comparisons between different ethnic groups. Ann Hematol; 2010 Feb;89(2):179-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequencies of non-Hodgkin's lymphoma subtypes in Kuwait: comparisons between different ethnic groups.
  • There is a wide variation in the prevalence of various subtypes of non-Hodgkin's lymphoma worldwide.
  • The aim of this study was to determine the relative frequency of different subtypes of non-Hodgkin's lymphoma in Kuwait based on the Revised European-American Lymphoma (REAL) classification.
  • From 1998 to 2006, 738 subjects were included that were registered with non-Hodgkin's lymphoma in the population-based cancer registry at the Kuwait Cancer Control Center.
  • We performed detailed immunohistochemical studies and classified subjects based on the REAL classification.
  • The prevalence of different types of non-Hodgkin's lymphoma was determined based on age, sex, site of disease, and ethnicity.
  • The prevalence of B- and T-cell lymphomas was 81.8% and 14.2%, respectively.
  • The three most common subtypes in Kuwaiti Arabs were diffuse large B-cell lymphoma (46.5%), follicular lymphoma (15.5%), and mycosis fungoides (9.3%).
  • In non-Kuwaiti Arabs, the most common subtypes were diffuse large B-cell lymphoma (48%), B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia (15.8%), and follicular lymphoma (12.7%).
  • Compared to the Western world, Kuwait had a lower prevalence of follicular lymphoma, a higher prevalence of diffuse large B-cell lymphoma and extranodal presentation, and a high frequency of mycosis fungoides.
  • Compared to other parts of Asia, Kuwait had a lower frequency of peripheral T-cell lymphomas.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / ethnology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711076.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Cossu A, Deiana A, Lissia A, Dedola MF, Cocco L, Palmieri G, Tanda F: Synchronous interdigitating dendritic cell sarcoma and B-cell small lymphocytic lymphoma in a lymph node. Arch Pathol Lab Med; 2006 Apr;130(4):544-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous interdigitating dendritic cell sarcoma and B-cell small lymphocytic lymphoma in a lymph node.
  • A diagnosis of an interdigitating dendritic cell tumor of the lymph node and a B-cell small lymphocytic lymphoma occurring in the same anatomic location was made.
  • We found that although rare cases of interdigitating dendritic cell tumor with an associated secondary malignancy have been described in the literature, to our knowledge, this is the first report of interdigitating dendritic cell tumor and synchronous neoplasm diagnosed at the same site.
  • [MeSH-major] Dendritic Cells / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Sarcoma / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Fatal Outcome. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Immunoglobulin Heavy Chains / genetics. Lymph Nodes / chemistry. Lymph Nodes / pathology. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594749.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


15. Roberts AW, Wilson W, Gandhi L, O'Connor OA, Rudin CM, Brown JR, Xiong H, Chiu Y, Enschede S, Krivoshik AP: Ongoing phase I studies of ABT-263: Mitigating Bcl-X<sub>L</sub> induced thrombocytopenia with lead-in and continuous dosing. J Clin Oncol; 2009 May 20;27(15_suppl):3505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ongoing phase 1 studies of ABT-263 show anti-tumor activity in CLL and some lymphomas (Wilson W et al, ASH. 2008).
  • We tested 2 strategies to mitigate variability in circulating platelet levels and achieve higher cumulative exposure: introducing a lower lead-in dose and using a continuous dosing (CD) (21/21 d schedule).
  • For pts receiving 150 mg lead-in, nadir occurred during this phase, and platelet levels remained relatively stable on CD for doses up to 225 mg.
  • While CD enrollment and time on study is still limited, anti-tumor activity includes 1 unconfirmed partial response (68% CT regression) in a SLL pt at 275 mg and 3 CLL pts with ≥50% lymphocyte reduction for ≥2 months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961281.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Vose JM: Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001. J Clin Oncol; 2009 May 20;27(15_suppl):8560

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001.
  • We conducted a phase II trial of single-agent lenalidomide in indolent non-Hodgkin's lymphoma (NHL).
  • Twenty-seven percent (6/22) of patients with follicular lymphoma grade 1 or 2, and 22% (4/18) of patients with small lymphocytic lymphoma responded to therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960983.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Wilson W, O'Connor OO, Roberts AW, Czuczman M, Brown J, Xiong H, Xiong H, Chiu Y, Krivoshik A, Enschede S, Humerickhouse R: ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). J Clin Oncol; 2009 May 20;27(15_suppl):8574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  • ABT-263 displays activity (EC<sub>50</sub> ≤ 1μM) against human lymphoid and small cell lung cancer cell lines.
  • Mechanism based preclinical toxicities include reductions in circulating lymphocytes, apoptosis of circulating platelets, and decreased spermatogenesis, mediated by inhibition of Bcl-2, Bcl-X<sub>L</sub>, and Bcl-w, respectively.
  • Among 27 CLL/SLL pts, 3 have confirmed radiographic partial responses (PR) (99%, 92% and 72%) and 2 have unconfirmed regressions, 51% and 72%.
  • 6 pts maintained a ≥50% decrease in circulating lymphocytes for ≥ 2 months and 11 pts have stable disease; of these 5 experienced minor radiographic responses (range of 36% to 49%).
  • In addition, among 40 (M06-814) lymphoma pts, 3 with follicular lymphoma achieved PR and one had a minor response (49% regression).
  • With CD dosing (16 pts), activity includes 1 unconfirmed PR in SLL & and 3 CLL pts with ≥50% lymphocyte reduction for ≥2 months duration.
  • CONCLUSIONS: ABT-263 showed favorable PK and safety profiles with anti-tumor activity in relapsed/refractory CLL/SLL and follicular lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962273.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Samuel S, Tumilasci VF, Oliere S, Liên-Anh Nguyên T, Shamy A, Bell J, Hiscott J: VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia. Mol Ther; 2010 Dec;18(12):2094-2103

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia.
  • In chronic lymphocytic leukemia (CLL), overexpression of antiapoptotic B-cell leukemia/lymphoma 2 (BCL-2) family members contributes to leukemogenesis by interfering with apoptosis; BCL-2 expression also impairs vesicular stomatitis virus (VSV)-mediated oncolysis of primary CLL cells.
  • In the effort to reverse resistance to VSV-mediated oncolysis, we combined VSV with obatoclax (GX15-070)'a small-molecule BCL-2 inhibitor currently in phase 2 clinical trials'and examined the molecular mechanisms governing the in vitro and in vivo antitumor efficiency of combining the two agents.
  • In combination with VSV, obatoclax synergistically induced cell death in primary CLL samples and reduced tumor growth in severe combined immunodeficient (SCID) mice-bearing A20 lymphoma tumors.
  • Combination treatment triggered the release of BAX from BCL-2 and myeloid cell leukemia-1 (MCL-1) from BAK, whereas VSV infection induced NOXA expression and increased the formation of a novel BAX-NOXA heterodimer.
  • These studies offer insight into the synergy between small-molecule BCL-2 inhibitors such as obatoclax and VSV as a combination strategy to overcome apoptosis resistance in CLL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28160637.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Soria-Céspedes D, Baquera-Heredia J, Pardo A, Ortiz-Hidalgo C: [Bilateral tonsillar hypertrophy as the first manifestation of B cell-small lymphocytic lymphoma with interfolicular pattern]. Rev Med Inst Mex Seguro Soc; 2010 Jan-Feb;48(1):75-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral tonsillar hypertrophy as the first manifestation of B cell-small lymphocytic lymphoma with interfolicular pattern].
  • [Transliterated title] Hipertrofia amigdalina bilateral como primera manifestación de linfoma de linfocitos pequeños B con patrón interfolicular.
  • B-cell small lymphocytic lymphoma typically involves nodal or extranodal tissues as a diffuse proliferation with proliferation centers (pseudofollicules) obliterating normal architecture.
  • But there are unusual patterns of involvement including interfollicular pattern that can be difficult to recognize histologically and probably represent partial or early involvement by neoplasm.
  • Tonsillar lymphoma usually presents either as a unilaterally enlarged palatine tonsil or as an ulcerative and fungating lesion over the tonsillar area.
  • Most lymphomas that involve the tonsil are diffuse large B cell lymphomas and primary low-grade lymphomas are exceptional.
  • We present a primary B-cell small lymphocytic lymphoma affecting palatine tonsils with interfollicular pattern in a 54 year-old man that clinically presented with symmetric / bilateral tonsillar enlargement and sleep apnea.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, B-Cell / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20696111.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


20. Andritsos L, Furman R, Flinn IW, Foreno-Torres A, Flynn JM, Stromatt SC, Byrd JC: A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL. J Clin Oncol; 2009 May 20;27(15_suppl):3017

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIP) in relapsed and refractory CLL.
  • Pre-clinical studies have demonstrated CD37 SMIP mediates significantly greater direct and NK-cell mediated killing of CLL cells as compared to other therapeutic antibodies used in CLL.
  • METHODS: Patients with relapsed/refractory CLL or SLL who had adequate organ function, platelets > 30,000/mm<sup>3</sup> were eligible.
  • Dose escalation and de-escalation is based on CTC AE toxicity grades.
  • Two patients had partial clearing of leukemia cutis, and the other six had 27-94% reduction in peripheral lymphocyte count.
  • One pt. had an increase in Hgb of 40% and a reduction in lymph nodes of 36%.
  • CONCLUSIONS: To date, TRU-016 is a well tolerated treatment with minimal infusional toxicity and no observed dose limiting toxicity.
  • Encouraging reduction in tumor lymphocyte blood counts, lymph node/spleen size and improvement in normal hematopoeitic function in patients with high risk genomic CLL have already been observed at low, non-saturating doses of CD37.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Cole J, Pantanowitz L, Aboulafia DM: Chronic lymphocytic leukemia (CLL) coexistent with HIV: An increasing association? J Clin Oncol; 2009 May 20;27(15_suppl):7078

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia (CLL) coexistent with HIV: An increasing association?
  • METHODS: Cases of HIV-associated CLL/small lymphocytic leukemia (SLL) were collected from the authors' archives and published case reports (using PubMed search).
  • Information regarding patient demographics (age, gender), mode of HIV acquisition, HAART use, immunosuppression (HIV Viral load [VL], CD4+ cell count), clinical presentation, pathology, and outcome were abstracted and analyzed.
  • CLL/SLL was diagnosed by lymph node biopsy (n = 1) and/or flow cytometry (n = 5).
  • Two patients remained well without treatment and 4 required therapy due to either hemolytic anemia, CLL- induced renal failure, pancytopenia, or hypogammaglobulinemia with recurrent infections.
  • CONCLUSIONS: CLL/SLL may occur in association with HIV infection in the elderly without significant concomitant immunosuppression.
  • CLL-related complications in our small series were frequent (67%), including mortality (50%).
  • Additional cases of CLL/SLL are anticipated as HIV-infected patients in the HAART era are reported to be living longer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961484.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lawce H, Olson S: FISH testing for deletions of chromosome 6q21 and 6q23 in hematologic neoplastic disorders. J Assoc Genet Technol; 2009;35(4):167-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosome 6q deletions are also commonly found in lymphoid malignancies such as acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), multiple myeloma (MM), mantle zone lymphoma (MZL), and Waldenström's macroglobulinemia (WM).
  • In childhood B- and T-cell ALL a deletion of 6q is the hallmark of a neutral prognosis; however, it may be cytogenetically obscure or cryptic, requiring interphase FISH analysis.
  • In adult ALL it indicates a favorable prognosis, but in CLL, B-cell small lymphocytic lymphoma (SLL), WM, and MM it has a poor prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952391.001).
  • [ISSN] 1523-7834
  • [Journal-full-title] Journal of the Association of Genetic Technologists
  • [ISO-abbreviation] J Assoc Genet Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Dores GM, Anderson WF, Curtis RE, Landgren O, Ostroumova E, Bluhm EC, Rabkin CS, Devesa SS, Linet MS: Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol; 2007 Dec;139(5):809-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology.
  • The 2001 World Health Organization classification scheme considers B-cell chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) in an aggregate category (CLL/SLL) because of shared clinicopathological features.
  • We have estimated age-adjusted incidence rates (IRs) of CLL and SLL in the population-based Surveillance, Epidemiology and End Results Program in the United States to analyse patterns of CLL and SLL separately and jointly.
  • Age-standardized to the 2000 US population, overall IRs were 3.83 per 100 000 person-years for CLL (n = 15 676) and 1.31 for SLL (n = 5382) during 1993-2004.
  • Incidence of the combined entity, CLL/SLL, was 90% higher among males compared to females, and the male:female IR ratio was significantly higher for CLL (1.98) than for SLL (1.67).
  • CLL/SLL IRs were 25% and 77% lower among Blacks and Asian/Pacific Islanders, respectively, compared to Whites.
  • A significant reporting delay was evident for CLL but not for SLL, so that CLL/SLL temporal trends must be interpreted cautiously.
  • CLL and SLL IRs increased exponentially with age among all gender/race groups, with CLL IRs increasing more steeply with advancing age than SLL.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17941952.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Intramural
  • [Publication-country] England
  •  go-up   go-down


24. Catrina Reading F, Schlette EJ, Stewart JM, Keating MJ, Katz RL, Caraway NP: Fine-needle aspiration biopsy findings in patients with small lymphocytic lymphoma transformed to hodgkin lymphoma. Am J Clin Pathol; 2007 Oct;128(4):571-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy findings in patients with small lymphocytic lymphoma transformed to hodgkin lymphoma.
  • Although small lymphocytic lymphoma (SLL) is an indolent lymphoma, approximately 5% of cases can transform to a higher-grade lymphoma, rarely Hodgkin lymphoma (HL).
  • We report the fine-needle aspiration (FNA) results of 6 cases of SLL/chronic lymphocytic leukemia (CLL) that transformed to HL.
  • The patients included 5 men and 1 woman, ranging in age from 49 to 72 years at the time of SLL/CLL diagnosis with time for development of HL ranging from 0 to 95 months (mean, 49.3 months).
  • The FNA diagnoses were SLL with HL transformation (2 cases), SLL with large atypical cells (1 case), and atypical lymphoid proliferation with large atypical cells (3 cases).
  • Flow cytometry performed in 5 cases (2 FNA specimens) demonstrated a monoclonal B-cell population with CD19/CD5 coexpression.
  • The presence of large atypical mononucleated and binucleated cells in lymph node FNA specimens from patients with SLL/CLL with progressive adenopathy should raise the possibility of transformation to HL.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Hodgkin Disease / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / virology. Female. Flow Cytometry. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Lymph Nodes / pathology. Male. Middle Aged. RNA, Viral / analysis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875507.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


25. Fehr M, Templeton A, Cogliatti S, Aebersold F, Egli F, Gillessen S, Cathomas R: Primary manifestation of small lymphocytic lymphoma in the prostate. Onkologie; 2009 Oct;32(10):586-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary manifestation of small lymphocytic lymphoma in the prostate.
  • BACKGROUND: Infiltration of non-haematopoietic organs by small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) is not unusual in late-stage disease and thus quite frequently encountered in post-mortem examinations.
  • However, primary manifestation of SLL/CLL in the prostate is rarely diagnosed.
  • PATIENTS AND METHODS: We report two cases of primary prostatic SLL/CLL, in one case in combination with prostate carcinoma, and discuss diagnostic pitfalls, pathophysiological mechanisms and therapeutic management, together with an overview of the literature.
  • CONCLUSIONS: Lymphocytic infiltration of the prostate associated with obstructive symptoms is rare but can already occur in very early disease.
  • Microscopically, SLL/CLL infiltration can be distinguished from chronic prostatitis by its pattern of infiltration and by immunohistochemistry.
  • As the incidence of both SLL/CLL and prostatic carcinoma increases with age, composite tumours might occur more often in the future.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2009 Oct;32(10):550-1 [19816069.001]
  • (PMID = 19816076.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 17
  •  go-up   go-down


26. Caraway NP, Thomas E, Khanna A, Payne L, Zhang HZ, Lin E, Keating MJ, Katz RL: Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival. Cancer; 2008 Oct 25;114(5):315-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival.
  • BACKGROUND: Fine-needle aspiration (FNA) of lymph nodes is commonly used to assess disease progression in patients with small lymphocytic lymphoma (SLL).
  • Although cytologic features are helpful for diagnosing typical SLL and transformed large-cell lymphoma (tLCL), SLL in accelerated phase (SLLacc) is more difficult to diagnose.
  • Additional tests are needed to identify those patients who are transforming to a higher-grade lymphoma.
  • This study evaluated the use of a multicolor fluorescence in situ hybridization (FISH) probe panel specifically designed for chronic lymphocytic leukemia (CLL)/SLL and assessed the association between FISH findings and cytologic diagnosis, proliferation index, and risk of death.
  • METHODS: FNA specimens from 50 patients (32 men and 18 women; mean age, 57 years [range, 36-77 years]) with histologically confirmed CLL and/or SLL were evaluated in this study for chromosomal abnormalities of 11q22 (ATM), 12, 13q14.3, 13q34.3 (LAMP1), and 17p13.1 (p53) by using a multiprobe FISH kit.
  • The FISH findings were compared with the cytologic diagnoses (26 SLLs, 12 SLLaccs, and 11 tLCLs), Ki-67 immunostaining, and risk of death.
  • CONCLUSIONS: FISH can be performed on FNA specimens from patients with a history of SLL/CLL.
  • Knowledge of genetic abnormalities from FNAs may be useful in deciding when and how to treat indolent or progressive SLL.
  • [MeSH-major] Biopsy, Fine-Needle. Chromosome Aberrations. In Situ Hybridization, Fluorescence. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / mortality

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18683215.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Thway K, Freeman A, Woodhouse CR, Fisher C: Epithelial-stromal tumor of seminal vesicle in a patient with chromophobe renal cell carcinoma and small lymphocytic lymphoma. Ann Diagn Pathol; 2008 Dec;12(6):433-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-stromal tumor of seminal vesicle in a patient with chromophobe renal cell carcinoma and small lymphocytic lymphoma.
  • In addition, this was associated with 2 synchronous malignant neoplasms, chromophobe renal cell carcinoma and small lymphocytic lymphoma, both of which were detected incidentally after clinical presentation because of the seminal vesicle mass.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma, Renal Cell / diagnosis. Genital Neoplasms, Male / diagnosis. Kidney Neoplasms / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Seminal Vesicles


28. Dillman RO, Schreeder MT, Hon JK, Connelly EF, DePriest C, Cutter K: Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer Biother Radiopharm; 2007 Apr;22(2):185-93
Hazardous Substances Data Bank. PENTOSTATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Community-based phase II trial of pentostatin, cyclophosphamide, and rituximab (PCR) biochemotherapy in chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • We conducted a multicenter, community-based phase II trial of PCR biochemotherapy (pentostatin 4 mg/m2, cyclophosphamide 600 mg/m2, and rituximab 375 mg/m2) every 3 weeks for up to 6 cycles in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • PCR is active in CLL/SLL, but appears to be less active and associated with more complications in the community setting, compared to trials with younger, lower risk patients who travel to academic referral centers for treatment.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / therapeutic use. Cyclophosphamide / therapeutic use. Delivery of Health Care. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Pentostatin / therapeutic use

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Choosing a Doctor or Health Care Service.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biother Radiopharm. 2007 Oct;22(5):713-4; author reply 715-7 [17979574.001]
  • (PMID = 17600465.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Membrane Glycoproteins; 143891-49-0 / TI 1 protein, Mustela vison; 395575MZO7 / Pentostatin; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


29. Iğdem S, Okkan S, Unalan B, Iğdem A, Ferhanoğlu B: Cervical cancer coexisting with small lymphocytic lymphoma detected during positron emission tomography/computed tomography simulation: a case report. Eur J Gynaecol Oncol; 2008;29(4):405-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer coexisting with small lymphocytic lymphoma detected during positron emission tomography/computed tomography simulation: a case report.
  • CASE: A 63-year-old woman who was deemed inoperable due to carcinoma of the cervical stump extending to the parametria and paraaortic lymph nodes detected on MR images presented for extended field radiotherapy.
  • The excisional biopsy was consistent with small lymphocytic lymphoma (SLL).
  • CONCLUSION: In our case, PET/CT simulation not only led to changes in treatment management, but also revealed a very rare coexistence of SLL and invasive squamous cell carcinoma of the cervix.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biopsy. Female. Fluorodeoxyglucose F18. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging / methods. Neoplasms, Second Primary / radiography. Neoplasms, Second Primary / radionuclide imaging. Radiopharmaceuticals. Whole Body Imaging / methods


30. Tsai HT, Cross AJ, Graubard BI, Oken M, Schatzkin A, Caporaso NE: Dietary factors and risk of chronic lymphocytic leukemia and small lymphocytic lymphoma: a pooled analysis of two prospective studies. Cancer Epidemiol Biomarkers Prev; 2010 Oct;19(10):2680-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary factors and risk of chronic lymphocytic leukemia and small lymphocytic lymphoma: a pooled analysis of two prospective studies.
  • BACKGROUND: Other than male sex, family history, advanced age, and race, risk factors for chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are unknown.
  • METHODS: Using two large prospective population-based studies, we evaluated the relationship between diet and CLL/SLL risk.
  • Among 525,982 men and women free of cancer at enrollment, we identified 1,129 incident CLL/SLL cases during 11.2 years of follow-up.
  • RESULTS: We found no associations between total fat, saturated fat, fiber, red meat, processed meat, fruit, or vegetable intake and risk of CLL/SLL.
  • We noted a suggestive positive association between body mass index and CLL/SLL (hazard ratio, 1.30; 95% confidence interval, 0.99-1.36).
  • CONCLUSION: We did not find any associations between food or nutrient intake and CLL/SLL.
  • IMPACT: Our large prospective study indicates that diet may not play a role in CLL/SLL development.
  • [MeSH-major] Diet. Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] Cancer Causes Control. 2008 Jun;19(5):491-503 [18204928.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):512-20 [15734980.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2871-6 [16385566.001]
  • [Cites] Am J Epidemiol. 2006 Dec 15;164(12):1222-32 [17005624.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1665-76 [15466985.001]
  • (PMID = 20929883.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010152-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS231483; NLM/ PMC3501724
  •  go-up   go-down


31. Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G: Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab. Leuk Res; 2010 Apr;34(4):454-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
  • In vitro studies of resistant human cell lines have confirmed that human concentrative nucleoside transporter 1 (hCNT1)-deficient cells display resistance.
  • EXPERIMENTAL DESIGN: We applied real-time PCR method to assess the mRNA expression of equilibrative and concentrative nucleoside transporter (hENT1, hCNT1), deoxycytidine and deoxyguanosine kinase (dCK, dGK), 5'-nucleotidase (5'-NT), ribonucleotide reductase catalytic and regulatory (RR1, RR2) subunits in bone marrow cells from 32 patients with Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) who received 2CdA-based chemotherapy.
  • RESULTS: All 32 patients enrolled expressed lower levels of hCNT1 as compared to healthy donors.
  • In univariate analysis, lower expression level of hCNT1 (p=0.0021) and RR2 (p=0.02) correlated with response to chemotherapy.
  • In particular, patients with low levels of hCNT1 achieved inferior clinical response.
  • This study suggests that nucleotidase expression levels can be used to identify subgroups of WM and SLL patients who will likely respond differently to a 2CdA-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cladribine / administration & dosage. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Membrane Transport Proteins / genetics. Waldenstrom Macroglobulinemia / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19647871.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 0 / Membrane Transport Proteins; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


32. Iczkowski KA, Gapin TB, Wajsman Z: Small lymphocytic lymphoma involving an enlarging complex renal cyst. Arch Pathol Lab Med; 2005 Jan;129(1):111-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small lymphocytic lymphoma involving an enlarging complex renal cyst.
  • Cervical lymph node biopsy had revealed small lymphocytic lymphoma.
  • Computed tomographic scan disclosed diffuse mesenteric and retroperitoneal adenopathy consistent with chronic lymphocytic leukemia, as well as a 4.5-cm complex cystic right renal mass, which 17 months later enlarged to 6.2 cm.
  • Partial nephrectomy revealed infiltration of the cyst wall by small lymphocytic lymphoma.
  • To our knowledge, this is the first reported case of lymphoma arising in or colonizing a renal cyst.
  • [MeSH-major] Kidney Diseases, Cystic / complications. Kidney Neoplasms / complications. Leukemia, Lymphocytic, Chronic, B-Cell / complications

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628890.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Tsimberidou AM, Wen S, O'Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ: Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol; 2007 Oct 10;25(29):4648-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center.
  • PURPOSE: Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are currently considered the same entity, but controversy remains over whether CLL and SLL should be treated similarly.
  • We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors.
  • METHODS: We searched the electronic database for patients with CLL or SLL who presented to The University of Texas M.D.
  • RESULTS: Among 2,126 consecutive CLL/SLL patients, 312 (15%) had ALC less than 5 x 10(9)/L.
  • CONCLUSION: Patients with CLL or SLL can be treated similarly.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphocyte Count
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD38 / biosynthesis. Diagnosis, Differential. Disease-Free Survival. Humans. Middle Aged. Prognosis. Texas. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17925562.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


34. Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, Greco FA: Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer; 2008 Mar 15;112(6):1288-95
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
  • BACKGROUND: The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first-line treatment for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • METHODS: In a nonrandomized phase 2 trial, 41 patients who had previously untreated CLL or SLL and required treatment received 4 cycles of the fludarabine and rituximab combination followed 5 weeks later by 4 weeks (12 doses) of intravenous alemtuzumab therapy.
  • RESULTS: Initial treatment with the combination of fludarabine and rituximab was well tolerated, and produced a 71% overall response rate (13% complete response).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / administration & dosage. Disease-Free Survival. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Rituximab. Survival Rate. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18189296.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


35. Ochoa Undargarain O, Hermida Pérez JA, Ochoa Montes de Oca J, Félix León JM: [Well-differentiated lymphocytic lymphoma of the prostate. Case report and bibliographic review]. Arch Esp Urol; 2006 Jun;59(5):538-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Well-differentiated lymphocytic lymphoma of the prostate. Case report and bibliographic review].
  • [Transliterated title] Linfoma linfocítico, bien diferenciado de la próstata, presentación de un caso y breve revisión de la literatura.
  • OBJECTIVE: To report a case of prostate lymphoma and a brief review of the literature.
  • Surgery with retropubic prostatectomy was performed, and pathology revealed a primary prostate lymphoma.
  • The case study is followed by a brief bibliographic review, where we analyse clinical menifestations of this entity, complementary studies useful for diagnosis (laboratory test, trasrectal prostate biopsy, transuretral resection, ultrasound and computerised axial tomography), treatment options (surgery, polychemotherapy, radiotherapy) as well as survival in these patients.
  • CONCLUSIONS: Of the cases reviewed, mean age at diagnosis was 57 years.
  • Clinical debut was with prostate symptoms, with or without AUR and sometimes manifestations of renal failure due to obstructive uropathy, as well as general symptoms (astenia, anorexia, weight loss).
  • PSA values remain unaltered in prostate lymphoma patients.
  • Histologic diagnosis may be made by transrectal prostate biopsy, although transurethral resection (TUR) may be necessary for confirmation.
  • Ultrasound and CT scan are of great utility for diagnosis of both local and distant tumors.
  • From a therapeutic point of view, surgery for the obstruction of the lower urinary tract (TURP or retropubic prostatectomy) may be necessary, as well as the cyclophosphamide based polychemotherapy with corticosteroids and other cytostatic agents, and radiotherapy; intratecal chemotherapy has also been used adjuvant bone marrow transplantation.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903560.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 26
  •  go-up   go-down


36. Kim T, Grobmyer SR, Dixon LR, Allan RW, Hochwald SN: Autoimmune pancreatitis and concurrent small lymphocytic lymphoma: not just a coincidence? J Gastrointest Surg; 2008 Sep;12(9):1566-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune pancreatitis and concurrent small lymphocytic lymphoma: not just a coincidence?
  • Computed tomography imaging revealed fullness of the pancreatic head and multiple enlarged retroperitoneal lymph nodes.
  • Several enlarged lymph nodes in the aortocaval region and a firm hard mass in the pancreatic head were found.
  • Frozen section from one of the lymph nodes was suspicious for low-grade lymphoma.
  • The retroperitoneal lymph nodes were involved by small lymphocytic lymphoma.
  • DISCUSSION: Autoimmune pancreatitis is the most common benign diagnosis after pancreatic resection for presumed malignancy.
  • It has a well-documented association with autoimmune conditions, such as Sjögren's syndrome, inflammatory bowel disease, and sclerosing cholangitis.
  • Additionally, chronic lymphocytic leukemia-small lymphocytic lymphoma is often associated with autoimmune phenomena, most notably autoimmune hemolytic anemia.
  • However, an association between autoimmune pancreatitis and small lymphocytic lymphoma has not been previously described.
  • To our knowledge, this is the first reported case of a patient with concurrent autoimmune pancreatitis and small lymphocytic lymphoma.
  • [MeSH-major] Autoimmune Diseases / complications. Autoimmune Diseases / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Pancreatitis / complications. Pancreatitis / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Blood Chemical Analysis. Cholangiography. Follow-Up Studies. Humans. Immunohistochemistry. Jaundice / diagnosis. Jaundice / etiology. Male. Pancreatic Function Tests. Pancreaticoduodenectomy / methods. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2006 Jul;41(7):613-25 [16932997.001]
  • [Cites] Dig Dis Sci. 1995 Jul;40(7):1561-8 [7628283.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1147-54 [18219538.001]
  • [Cites] Gastroenterology. 1996 May;110(5):1579-86 [8613065.001]
  • [Cites] Blood. 1962 Jan;19:23-37 [13889001.001]
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1197-205 [17287899.001]
  • [Cites] N Engl J Med. 2001 Mar 8;344(10):732-8 [11236777.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):1010-6; quiz 934 [16843735.001]
  • [Cites] Am Surg. 2008 Jul;74(7):654-8 [18646484.001]
  • [Cites] Am J Gastroenterol. 2007 Nov;102(11):2417-25 [17894845.001]
  • [Cites] Pancreas. 2004 Aug;29(2):167 [15257110.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1119-27 [12883244.001]
  • [Cites] Arch Intern Med. 1974 Oct;134(4):721-4 [4415396.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1689-92 [17145607.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):387-95 [2050373.001]
  • [Cites] Gut. 1997 Aug;41(2):263-8 [9301509.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):129-37; discussion 137-9 [12559194.001]
  • [Cites] Gastroenterology. 1982 Dec;83(6):1177-82 [7129026.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2141-8 [10445541.001]
  • [Cites] Am J Dig Dis. 1961 Jul;6:688-98 [13746542.001]
  • [Cites] Leuk Lymphoma. 2007 Jun;48(6):1072-80 [17577769.001]
  • [Cites] Ann Surg. 2003 Jun;237(6):853-8; discussion 858-9 [12796582.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] J Gastroenterol. 2007 May;42 Suppl 18:9-14 [17520217.001]
  • [Cites] Leukemia. 1992 Nov;6 Suppl 4:152-4 [1434818.001]
  • [Cites] Dig Dis Sci. 1997 Jul;42(7):1458-68 [9246047.001]
  • [Cites] Gut. 2007 Dec;56(12):1719-24 [17525092.001]
  • (PMID = 18506547.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Hauswirth AW, Födinger M, Fritz M, Müllauer L, Simonitsch-Klupp I, Streubel B, Chott A, Sperr WR, Jäger U, Valent P: Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. Hum Pathol; 2008 Jun;39(6):917-24
Genetic Alliance. consumer health - Systemic mastocytosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease.
  • Patients with systemic mastocytosis (SM) may acquire an associated hematologic non-mast cell (MC)-lineage disease (AHNMD).
  • In most cases, a myeloid neoplasm is diagnosed, whereas the occurrence of a lymphoproliferative disease is an extremely rare event.
  • We report on a patient with indolent SM associated with small lymphocytic lymphoma (SLL).
  • The patient presented with lymphadenopathy, maculopapular exanthema, and elevated serum tryptase.
  • The bone marrow biopsy showed focal MC aggregates together with SLL.
  • As assessed by immunostaining, neoplastic MC were found to exhibit CD117 and CD25 but did not display CD5 or CD20, whereas SLL cells were found to coexpress CD5 and CD20 but did not express MC antigens.
  • The KIT mutation D816V was detected in sorted CD34(+) cells and unfractionated marrow cells but not in CD5(+) SLL cells, confirming the coexistence of 2 distinct neoplasms.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Mastocytosis, Systemic / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Bone Marrow Cells / metabolism. Bone Marrow Cells / pathology. DNA Mutational Analysis. DNA, Neoplasm / analysis. Flow Cytometry. Humans. Male. Middle Aged. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Mast cell disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448146.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


38. Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC: A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia; 2009 May;23(5):912-8
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
  • Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma but is associated with tumor necrosis factor-alpha (TNF-alpha) release that can cause CLL proliferation and inhibit apoptosis.
  • The combination of etanercept and thrice weekly rituximab produces durable remissions in non-del(17p13.1) CLL patients and is well tolerated.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Haematologica. 2006 Jun;91(6 Suppl):ECR23 [16785126.001]
  • [Cites] Lancet. 2007 Jul 21;370(9583):230-9 [17658394.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Sep;20(3):455-68 [17707833.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1962-3 [10561242.001]
  • [Cites] Cancer Immunol Immunother. 2000 Mar;48(12):673-83 [10752475.001]
  • [Cites] Blood Cells Mol Dis. 2000 Apr;26(2):133-43 [10753604.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Med Oncol. 2000 Aug;17(3):203-10 [10962531.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2153-64 [11304767.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2165-70 [11304768.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1326-31 [11520778.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] Blood. 2002 Feb 1;99(3):754-8 [11806974.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Sep;50(3):237-42 [12203106.001]
  • [Cites] Blood. 2003 Jan 1;101(1):6-14 [12393429.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):36-8 [12517774.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3940-7 [12975461.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1472-4 [14563637.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Cancer. 1994;30A(9):1259-63 [7999409.001]
  • [Cites] Blood. 1995 Jan 15;85(2):307-18 [7811987.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):5038-45 [7594512.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Immunol Cell Biol. 1997 Apr;75(2):127-35 [9107564.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4342-9 [9596683.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Eur J Haematol. 1999 Feb;62(2):76-82 [10052709.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):791-5 [10071268.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Immunol Methods. 2005 Sep;304(1-2):88-99 [16109421.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):437-43 [16344317.001]
  • [Cites] Blood. 2006 Feb 1;107(3):885-91 [16219797.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):266-72 [16755224.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):793-8 [17283364.001]
  • (PMID = 19225537.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA095426; United States / NCI NIH HHS / CA / P01 CA9542
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; 4F4X42SYQ6 / Rituximab; FA2DM6879K / Vidarabine; OP401G7OJC / Etanercept; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS79899; NLM/ PMC4099250
  •  go-up   go-down


39. McElroy C, Velilla R, Chaudhary H, Al-Abbadi MA: Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature. Diagn Cytopathol; 2009 Jan;37(1):48-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration diagnosis of squamous cell carcinoma in a lymph node involved with small lymphocytic lymphoma: case report and review of the literature.
  • Diagnosis of two distinct malignant entities existing concurrently and at the same location (synchronous malignancy) by fine- needle aspiration (FNA) is unusual but may occur.
  • Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) in particular is associated with an increased incidence of secondary tumor, likely due to associated immunodeficiency.
  • Co-occurrence of some carcinomas such as squamous cell carcinoma (SCC), may show especially aggressive behavior.
  • A 57-year-old Caucasian male presented with recurrent upper extremity lymphedema and diffuse lymphadenopathy of the axillary and cervical regions.
  • FNA of a large cervical lymph node was diagnostic for both atypical lymphocytic proliferation and SCC.
  • Flow cytometric analysis showed the atypical lymphocytic proliferation to be positive for CD5, CD23, CD19, CD20, HLA-DR, CD38, and the population was kappa light chain restricted.
  • These cells were negative for CD-10 and FMC-7 antigens, suggesting a phenotype of B-cell SLL/CLL.
  • We report a rare occurrence of metastatic SCC to a lymph node infiltrated by SLL/CLL.
  • The diagnosis was achieved by a combination of cytomorphologic examination of FNA smears, immunohistochemical staining of cell block material, and flow cytometry on the sample obtained by FNA.
  • To the best of our knowledge, only three cases of SCC metastasis to SLL/CLL diagnosed by FNA have been reported in the English literature.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymph Nodes / pathology. Neoplasms, Multiple Primary / diagnosis. Oropharyngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973126.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 16
  •  go-up   go-down


40. Leuenberger M, Frigerio S, Wild PJ, Noetzli F, Korol D, Zimmermann DR, Gengler C, Probst-Hensch NM, Moch H, Tinguely M: AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations. Mod Pathol; 2010 Feb;23(2):177-86
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AID protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma is associated with poor prognosis and complex genetic alterations.
  • The biological behavior of chronic lymphocytic leukemia and small lymphocytic lymphoma is unpredictable.
  • Nonetheless, non-mutated IgV(H) gene rearrangement, ATM (11q22-23) and p53 (17p13) deletion are recognized as unfavorable prognosticators in chronic lymphocytic leukemia.
  • The mRNA expression of activation-induced cytidine deaminase (AID), an enzyme indispensable for somatic hypermutation processes, was claimed to be predictive of non-mutated chronic lymphocytic leukemia cells in blood.
  • Here, we evaluated AID protein expression compared with known molecular and immunohistochemical prognostic indicators in 71 chronic lymphocytic leukemia/small lymphocytic lymphoma patients using a tissue microarray approach.
  • Twenty-five percent (17/69) of patients with AID-positive chronic lymphocytic leukemia/small lymphocytic lymphoma displayed a shorter survival than AID-negative chronic lymphocytic leukemia/small lymphocytic lymphoma patients (61 vs 130 months, P=0.001).
  • Taken together, our study shows that AID expression is an indicator of an unfavorable prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma patients, although it is not a surrogate marker for the IgV(H) status.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cytidine Deaminase / biosynthesis. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Leukemia, Lymphocytic, Chronic, B-Cell / genetics

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19898425.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; EC 3.5.4.- / AICDA (activation-induced cytidine deaminase); EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


41. Li S, Mann KP, Holden JT: Composite small lymphocytic lymphoma and extra-medullary myeloid tumor: a potential diagnostic pitfall. Int J Clin Exp Pathol; 2008;1(1):91-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Composite small lymphocytic lymphoma and extra-medullary myeloid tumor: a potential diagnostic pitfall.
  • Reported herein is a case of composite small lymphocytic lymphoma (SLL) and extramedullary myeloid tumor (EMT) occurring in the same lymph node.
  • Routine morphologic examination revealed a diffuse proliferation of small mature lymphocytes with numerous irregularly dispersed nodules, closely resembling SLL with prominent proliferation centers or Richter's transformation.
  • Flow cytometric immunophenotyping and immunohistochemical stains demonstrated the presence of SLL cells as well as myeloblasts, confirming the diagnosis of a composite SLL and EMT.
  • In conclusion, the occurrence of SLL and EMT in the same lymph node is rare and multiparameter approach is essential for a definitive diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2343-51 [16710033.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):250-6 [16616072.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):683-90 [16524977.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):445-52 [16191514.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Histopathology. 1999 May;34(5):391-8 [10231412.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Am J Surg Pathol. 1993 Oct;17(10):1011-9 [8372941.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):205-12 [12579990.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):957-68 [12213724.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):624-9 [11979092.001]
  • [Cites] Arch Pathol Lab Med. 1995 Sep;119(9):790-8 [7668936.001]
  • (PMID = 18784827.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480536
  • [Keywords] NOTNLM ; Extramedullary myeloid tumor / flow cytometric immunophenotyping / fluorescence in situ hybridization / immunohistochemistry / karyotype / small lymphocytic lymphoma
  •  go-up   go-down


42. El Demellawy D, Ross C, Sur M, Alowami S: Synchronously diagnosed lymph nodal collision tumor of malignant melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report. Diagn Pathol; 2007;2:34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronously diagnosed lymph nodal collision tumor of malignant melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: case report.
  • We report a case of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma and malignant melanoma (MM) occurring synchronously in the same lymph node.
  • To our knowledge this is the first time that synchronous occurrence of these two malignant processes in the same tissue is described.
  • In this case it is important that the melanoma was recognized in the excised lymph node, as this finding had much more critical treatment and long term survival consequences.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Melanoma Res. 2001 Oct;11(5):517-22 [11595890.001]
  • [Cites] Surgery. 2002 Feb;131(2):216-8 [11854704.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2002 Sep;16(5):491-3 [12428845.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Leuk Lymphoma. 2006 Mar;47(3):553-6 [16396780.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Cell Immunol. 1995 Sep;164(2):189-202 [7656327.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Immunol Today. 1994 Apr;15(4):174-9 [8198709.001]
  • [Cites] Curr Opin Oncol. 1995 Sep;7(5):421-5 [8541386.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2325-31 [8635103.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • (PMID = 17760975.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2040134
  •  go-up   go-down


43. Steinmetz C, Shabaik A, Hasteh F: Systemic mastocytosis associated with small lymphocytic lymphoma: an incidental finding in a patient with invasive gastric adenocarcinoma. Diagn Cytopathol; 2007 Nov;35(11):728-33
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic mastocytosis associated with small lymphocytic lymphoma: an incidental finding in a patient with invasive gastric adenocarcinoma.
  • We report an interesting case of systemic mastocytosis diagnosed incidentally in an omental lymph node in the setting of an invasive gastric adenocarcinoma.
  • The Diff-Quick touch preparation of the lymph node revealed abundant single cells and loose aggregates of cells with round to oval nuclei and deeply basophilic granules.
  • Monotonous proliferation of small mature lymphocytes and many eosinophils were also present in the background.
  • The frozen section and permanent sections of lymph node showed partial to complete replacement of lymph node by neoplastic mast cells.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Mastocytosis, Systemic / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology


44. Ding W, Zent CS: Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/ small lymphocytic lymphoma. Clin Adv Hematol Oncol; 2007 Apr;5(4):257-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/ small lymphocytic lymphoma.
  • Autoimmune cytopenia is an important but poorly understood clinical complication of chronic lymphocytic leukemia/ small lymphocytic lymphoma.
  • We review the pathogenesis, clinical presentation, and management of autoimmune hemolytic anemia, immune thrombocytopenia, and pure red blood cell aplasia in patients with chronic lymphocytic leukemia/ small lymphocytic lymphoma.
  • [MeSH-major] Agranulocytosis / diagnosis. Anemia, Hemolytic, Autoimmune / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell. Purpura, Thrombocytopenic, Idiopathic / diagnosis. Red-Cell Aplasia, Pure / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Male

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607284.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


45. Daudignon A, Poulain S, Morel P, Penther D, Parmentier F, Bouchindhomme B, Fernandes J, Duthilleul P, Bastard C: Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphoma. Leuk Res; 2010 May;34(5):580-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphoma.
  • Small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL) are considered as similar entity by the WHO classification.
  • We assessed the distribution of the four prognostic cytogenetic markers (deletion 11q23, 13q14, 17p13 and trisomy 12) and VH mutational status in 32 SLL and 119 CLL.
  • Trisomy 12 was most frequent (36% vs 13%, p=0.014) and 13q14 deletion was less frequent (9% vs 44%, p=0.001) in SLL in comparison with CLL.
  • An over representation of VH3-21 gene usage was found in SLL (17% vs 1%, p=0.011).
  • In conclusion, SLL show specific genetic markers that distinguish them from classical CLL.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosomes, Human, Pair 12 / genetics. Genes, Immunoglobulin Heavy Chain / genetics. Immunoglobulin Variable Region / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Trisomy / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA Mutational Analysis. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Mutation. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19959229.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Variable Region
  •  go-up   go-down


46. Asaad NY, Abd El-Wahed MM, Dawoud MM: Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL). J Egypt Natl Canc Inst; 2005 Dec;17(4):279-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and prognosis of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL).
  • BACKGROUND: B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma (B-CLL/SLL) and mantle cell lymphoma (MCL) show many overlapping morphologic and immunophenotyping features, however they have great difference in therapeutic regimens and prognosis.
  • THE AIM OF THE STUDY: Is to determine the diagnostic and prognostic role of clinico-pathologic variables, CD23 and Cyclin D1 oncoprotiens in B-SLL/CLL and MCL.
  • PATIENTS AND METHODS: This study included 25 BCLL/ SLL cases and 25 MCL cases.
  • RESULTS: There was significant difference between BCLL/ SLL and MCL regarding several items including pattern of growth, where interfollicular pattern was restricted to B-SLL/CLL while nodular and mantle zone pattern were confined to MCL; pseudo-follicles were only present in B-CLL/SLL.
  • Transformed cells, plasmacytoid cells, peripheral blood lymphocytosis, significant longer survival and good prognosis were statistically more prominent in favor of B-CLL/SLL.
  • On the other hand, cell cleavage, epithelioid histiocytes, plasma cells, naked nuclei, hyalinized venules, deposited hyaline material in background and reticular fibers in addition to higher mitotic index per 20 HPF were more significantly identified in favor of MCL.
  • CD23 was expressed as membranous pattern in 16/25 (64%) of B-CLL/SLL cases and 1/25 (4%) of MCL cases.
  • On the other hand, Cyclin D1 was expressed as nuclear staining in 18/25 (72%) of MCL cases and only 1/25 (4%) of B-CLL/SLL cases.
  • Regarding B-CLL/SLL, age >60 years and mitosis >or=10/20 HPF were independent prognostic factors of shorter survival by multivariate analysis.
  • CONCLUSION: Cyclin D1 is not only implicated in tumor genesis of MCL, but also in progression and extension of the disease when expressed in high levels (50% cut off value) and it seems to have prognostic impact in MCL.
  • This can be used as a basis for future therapeutic strategies targeting cell cycle regulators.
  • This study could support the concept that Cyclin D1 and CD23 immunostaining may be reliable diagnostic tools for discrimination between B-CLL/SLL and MCL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, Mantle-Cell / diagnosis
  • [MeSH-minor] Cyclin D1 / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Middle Aged. Prognosis. Receptors, IgE / metabolism. Survival Analysis


47. Donovan A, Schweitzer ME, Garcia RA, Nomikos G: Chronic lymphocytic leukemia/small lymphocytic lymphoma presenting as septic arthritis of the shoulder. Skeletal Radiol; 2008 Nov;37(11):1035-9
Genetic Alliance. consumer health - Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia/small lymphocytic lymphoma presenting as septic arthritis of the shoulder.
  • Biopsy performed to assess for possible osteomyelitis demonstrated chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • Intra-articular lymphoma is a rare but important consideration in patients with atypical clinical presentation.
  • Imaging alone may be insufficient to render diagnosis as lymphoma can mimic infection, synovial hypertrophic processes, and depositional arthropathy.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Shoulder Pain / diagnosis
  • [MeSH-minor] Arthritis, Infectious / diagnosis. Biopsy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 1998 Jan;27(1):33-5 [9507608.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):1000-10 [8712287.001]
  • [Cites] Ann Diagn Pathol. 2007 Oct;11(5):363-89 [17870025.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jan;182(1):119-22 [14684523.001]
  • [Cites] Rheumatol Int. 2005 Sep;25(7):565-6 [15959785.001]
  • [Cites] Radiology. 1994 May;191(2):413-9 [8153315.001]
  • [Cites] Eur J Cancer Care (Engl). 2004 Jul;13(3):279-87 [15196232.001]
  • [Cites] Skeletal Radiol. 1995 Jan;24(1):7-12 [7709261.001]
  • [Cites] Br J Clin Pract. 1982 Sep;36(9):327-8 [7150468.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):761-9 [12933477.001]
  • [Cites] Ann Hematol. 2002 Jun;81(6):299-303 [12107557.001]
  • [Cites] J Arthroplasty. 1999 Jan;14 (1):108-11 [9926962.001]
  • [Cites] Arthroscopy. 2007 Apr;23(4):447.e1-4 [17418346.001]
  • [Cites] Rheumatology (Oxford). 2004 Mar;43(3):391 [14963210.001]
  • [Cites] Arthritis Rheum. 1987 Feb;30(2):155-61 [3827957.001]
  • [Cites] J Bone Joint Surg Am. 2006 Dec;88(12):2730-4 [17142425.001]
  • [Cites] Ann Rheum Dis. 2002 Jun;61(6):493-8 [12006320.001]
  • [Cites] AJR Am J Roentgenol. 1998 May;170(5):1243-7 [9574594.001]
  • [Cites] Tuber Lung Dis. 1993 Dec;74(6):399-404 [8136494.001]
  • (PMID = 18521594.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


48. Kastenbaum HA, Khalbuss WE, Felgar RE, Stoller R, Monaco SE: The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology. Cytojournal; 2010;7:20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology.
  • BACKGROUND: The cytologic diagnosis of Small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) often relies on finding a small lymphoid population with the characteristic immunoprofile by ancillary testing.
  • There are only a few reports of other processes identified with SLL/CLL.
  • The aim of this study was to review the fine needle aspiration (FNA) and touch prep (TP) diagnoses of SLL/CLL in order to identify any coincident entities.
  • MATERIALS AND METHODS: We retrospectively reviewed all FNA and TP cytology cases between January 2005 and May 2009 with a diagnosis of SLL/CLL to determine the presence of any coincident process.
  • Coincident entities were identified in nine cases (31%) and included seven (28%) neoplastic entities (Hodgkin lymphoma [HL], adenocarcinoma, squamous cell carcinoma, seminoma) and two (7%) non-neoplastic entities (infection and immunoglobulin containing cells).
  • Six cases (21%) suspicious for large cell transformation were also identified.
  • CONCLUSION: In our review of SLL/CLL, coincident entities were present in 31% of the cases and included a spectrum of non-neoplastic and neoplastic processes.
  • FC was the most frequently utilized ancillary test, but IHC provided important information by excluding a mantle cell lymphoma or confirming a coincident process.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20976208.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2955352
  • [Keywords] NOTNLM ; Chronic lymphocytic leukemia / SLL/CLL / cytopathology / small lymphocytic lymphoma
  •  go-up   go-down


49. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL: Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma; 2009 Aug;50(8):1261-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis.
  • Improved medical care could have altered the clinical presentation and survival of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) complicated by autoimmune disease cytopenia (AID cytopenia).
  • When compared with the historical reported data, our study shows a lower rate of autoimmune hemolytic anemia (2.3%), and similar rates of immune thrombocytopenia (2.0%), and pure red blood cell aplasia (0.5%).
  • AID cytopenia occurred at all stages of CLL, responded well to treatment, did not alter overall survival, and contributed to death in only 6 (12%) patients.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 May 1;95(9):2786-92 [10779422.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Blood. 2001 Jul 1;98(1):181-6 [11418478.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1325-30 [11571749.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2092-5 [12357362.001]
  • [Cites] Br J Haematol. 2003 Apr;121(2):287-95 [12694251.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):1-8 [12949883.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Blood. 1975 Aug;46(2):219-34 [1139039.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):198-206 [7237385.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):713-6 [3488334.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Br J Haematol. 1995 Oct;91(2):341-4 [8547072.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] Blood. 2005 Jan 1;105(1):49-53 [15138165.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] Leuk Lymphoma. 2006 Sep;47(9):1738-46 [17064983.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1110-6 [17986663.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1820-6 [18055869.001]
  • [Cites] Br J Haematol. 2008 May;141(5):615-21 [18373706.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5446-56 [18216293.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 19811329.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ NIHMS548896; NLM/ PMC3917557
  •  go-up   go-down


50. Soma LA, Craig FE, Swerdlow SH: The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum Pathol; 2006 Feb;37(2):152-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • Prognostication in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) based, in part, on ZAP-70 and CD38 expression, and to a lesser extent, on MUM1/IRF4 expression, is currently of great interest.
  • The more aggressive type of CLL/SLL is reportedly characterized by neoplastic cells that are more responsive to B-cell signaling with proliferation centers (PCs), a potentially important site of neoplastic cell stimulation.
  • To study the relationship of these markers to each other and to the pattern of PCs, immunohistochemical stains for ZAP-70 and MUM1/IRF4 were performed and the PC patterns assessed (where possible) in 29 tissue biopsies with CLL/SLL.
  • Seven cases, none with atypical PC, also showed uniform positivity throughout, 14 showed weaker staining of surrounding lymphocytes, and 8 had PC staining only.
  • These findings highlight the complex interrelationship of prognostic markers in CLL/SLL and demonstrate potentially important microenvironmental variations in their expression.
  • They support the hypothesis that PCs are a site for B-cell receptor signaling, which helps explain reported site-dependent antigenic variation in CLL/SLL, and suggest that PC morphology may correlate with other biological features.
  • [MeSH-major] Biomarkers, Tumor / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD38 / biosynthesis. Cell Proliferation. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Interferon Regulatory Factors / biosynthesis. Male. Membrane Glycoproteins / biosynthesis. Prognosis. ZAP-70 Protein-Tyrosine Kinase / biosynthesis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426914.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factors; 0 / Membrane Glycoproteins; 0 / interferon regulatory factor-4; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  •  go-up   go-down


51. Yin CC, Lin P, Carney DA, Handy BC, Rassidakis GZ, Admirand JH, Keating MJ, Medeiros LJ: Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. Am J Clin Pathol; 2005 Apr;123(4):594-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein.
  • We studied the clinicopathologic, immunophenotypic, and cytogenetic features of 26 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) associated with serum IgM paraprotein.
  • The study group (16 men; 10 women; median age, 64 years; range, 40-82 years) represents approximately 2.5% of CLL/SLL cases at our institution.
  • The paraprotein level ranged from 1 to 14 g/L (median, 4 g/L).
  • Neoplasms in bone marrow were composed of small round lymphocytes arranged in nodular (n = 6), diffuse (n = 5), interstitial (n = 5), or mixed (n = 10) patterns.
  • The overall survival of this group (median follow-up, 24 months) was not significantly different from that for an age-, sex-and stage-matched group of 52 CLL/SLL patients without IgM paraprotein (P = .60).
  • We conclude that CLL/SLL cases with serum IgM paraprotein are similar to other CLL/SLL cases in their clinicopathologic and immunophenotypic features.
  • [MeSH-major] Immunoglobulin M / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Paraproteins / immunology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15743747.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M; 0 / Paraproteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


52. Reid-Nicholson M, Moreira A, Ramalingam P: Cytologic features of mixed papillary carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma of the thyroid gland. Diagn Cytopathol; 2008 Nov;36(11):813-7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of mixed papillary carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma of the thyroid gland.
  • We report a case of papillary thyroid carcinoma (PTC) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma of the thyroid gland.
  • Fine-needle aspiration biopsy (FNAB) was performed and revealed PTC and an atypical lymphoid infiltrate that was suspicious for lymphoma.
  • A partial thyroidectomy was performed and confirmed PTC with concurrent gland involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL).
  • [MeSH-major] Carcinoma, Papillary / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Thyroid Neoplasms / pathology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831028.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Peinert S, Seymour JF: Indolent lymphomas other than follicular and marginal zone lymphomas. Hematol Oncol Clin North Am; 2008 Oct;22(5):903-40, viii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indolent lymphomas other than follicular and marginal zone lymphomas.
  • This article addresses two of the less common entities among clinically indolent B-cell non-Hodgkin lymphomas: small lymphocytic lymphoma and lymphoplasmacytic lymphoma, also known as "Waldenstrom's macroglobulinemia."
  • Differential diagnoses and prognostic factors are discussed for each as well as new treatment options and stem cell transplantation.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Stem Cell Transplantation. Waldenstrom Macroglobulinemia / pathology. Waldenstrom Macroglobulinemia / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18954743.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 265
  •  go-up   go-down


54. Irons RD, Le A, Bao L, Zhu X, Ryder J, Wang XQ, Ji M, Chen Y, Wu X, Lin G: Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns. Leuk Res; 2009 Dec;33(12):1599-603
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns.
  • The clinical, cytogenetic and molecular features of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), a disease previously considered to be rare in Asia, were examined in consecutive series of 70 cases diagnosed by our laboratory over a 30-month period.
  • Clonal abnormalities were observed in 80% of CLL/SLL cases using a combination of conventional cytogenetic and fluorescence in situ hybridization (FISH) analysis.
  • IgV(H) gene mutation status was a significant predictor of initial survival in CLL/SLL.
  • [MeSH-major] Genes, Immunoglobulin. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Mutation

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19428103.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


55. Singh I, Joshi M, Agarwal S, Singh UR, Saran R: Extra-nodal small cell lymphocytic lymphoma of prostate: an unusual cause of lower urinary tract symptoms. Urology; 2008 Mar;71(3):547.e7-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-nodal small cell lymphocytic lymphoma of prostate: an unusual cause of lower urinary tract symptoms.
  • Malignant lymphoma of the prostate is a rare occurrence.
  • We describe a case of 60-year-old man presenting with acute urinary retention due to small cell lymphocytic secondary lymphoma of the prostate.
  • We present the clinical manifestation of the disease emphasizing that all lower urinary tract symptom (LUTS) cases should be evaluated for the potential that metastatic cancers or lymphomas may present with such a diagnosis.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / complications. Prostatic Neoplasms / complications. Urethral Obstruction / etiology. Urinary Bladder Neck Obstruction / etiology. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342214.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


56. Sullu Y, Donmez G, Kandemir B, Gun S: Renal cell carcinoma with non-Hodgkin's lymphoma infiltration: a case report. Pathol Res Pract; 2007;203(8):625-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cell carcinoma with non-Hodgkin's lymphoma infiltration: a case report.
  • The coexistence of renal cell carcinoma and non-Hodgkin's lymphoma is more common than expected in the general population; however, renal cell carcinoma with infiltration by non-Hodgkin's lymphoma has rarely been reported.
  • Here we report on a 77-year-old patient who presented with small lymphocytic lymphoma in the jugulodigastric lymph node.
  • On histopathological examination, the mass was diagnosed as a grade III renal cell carcinoma with infiltrated small lymphocytic lymphoma that was positive for B-cells (CD20).
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662539.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20
  •  go-up   go-down


57. Fraser CR, Wang W, Gomez M, Zhang T, Mathew S, Furman RR, Knowles DM, Orazi A, Tam W: Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone. Am J Clin Pathol; 2009 Dec;132(6):928-39
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma to interdigitating dendritic cell sarcoma: evidence for transdifferentiation of the lymphoma clone.
  • Interdigitating dendritic cell sarcoma (IDCS) is a rare tumor derived from interdigitating dendritic cells.
  • Three cases of IDCS associated with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have been described, but no clonal relationship between the 2 neoplasms was demonstrated.
  • We present a detailed case analysis of a CLL/SLL with metachronous IDCS and demonstrate that these 2 neoplasms are clonally related.
  • Our study demonstrates for the first time clonal transformation of CLL/SLL into IDCS.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Dendritic Cell Sarcoma, Interdigitating / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Neoplasms, Multiple Primary
  • [MeSH-minor] Aged. Bone Marrow Cells / chemistry. Bone Marrow Cells / pathology. Cell Transdifferentiation. Chromosomes, Human, Pair 12. Clone Cells. Gene Rearrangement, B-Lymphocyte, Heavy Chain / genetics. Humans. Lymph Nodes / chemistry. Lymph Nodes / pathology. Male. RNA, Neoplasm / analysis. Trisomy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926586.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  •  go-up   go-down


58. Okulicz JF, Lloyd BA, Krause JO, Conger NG: Mycobacterium tuberculosis infection of a presumed Charcot joint. South Med J; 2005 Sep;98(9):924-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 65-year-old male with peripheral neuropathy and small lymphocytic lymphoma presented with erythema and edema of the left foot.
  • [MeSH-major] Arthropathy, Neurogenic / diagnosis. Diagnostic Errors. Mycobacterium tuberculosis / isolation & purification. Tuberculosis, Osteoarticular / diagnosis. Tuberculosis, Osteoarticular / microbiology
  • [MeSH-minor] Aged. Antitubercular Agents / therapeutic use. Drug Therapy, Combination. Foot Ulcer / drug therapy. Foot Ulcer / microbiology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Male. Peripheral Nervous System Diseases / complications. Synovial Fluid / microbiology

  • Genetic Alliance. consumer health - Tuberculosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217986.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


59. Shin J, Chute D, Milas M, Mitchell J, Siperstein A, Berber E: A rare case of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting in the thyroid gland. Thyroid; 2010 Sep;20(9):1019-23
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare case of chronic lymphocytic leukemia/small lymphocytic lymphoma presenting in the thyroid gland.
  • BACKGROUND: Lymphoma involving the thyroid gland is rare.
  • Diffuse large B-cell lymphoma and mucosa-associated lymphoid tissue lymphoma are the two most common histologic subtypes of primary thyroid lymphoma.
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) presenting initially as a thyroid abnormality is extremely rare, with very few reported cases in the literature.
  • The sonographic finding of a distinct thyroid nodule in the heterogeneous background of chronic lymphocytic thyroiditis led to the performance of a fine-needle aspiration biopsy and flow cytometry, with a high index of suspicion for thyroid lymphoma.
  • Subsequent surgical removal of the thyroid gland, prompted by the patient's history of head and neck radiation, confirmed the diagnosis of CLL/SLL.
  • Although thyroiditis has long been associated with lymphoma arising in the thyroid gland, CLL/SLL involving the thyroid has not been linked to chronic lymphocytic thyroiditis.
  • CONCLUSIONS: Due to the rarity of thyroid lymphomas, our experience in the detection and management of this disease is limited.
  • Primary thyroid lymphoma should be suspected in a patient with a history of chronic lymphocytic thyroiditis presenting with a rapidly enlarging neck mass.
  • The initial diagnostic method for thyroid lymphoma should consist of a fine-needle aspiration biopsy with the use of ancillary techniques such as flow cytometry and immunohistochemistry for improved diagnostic accuracy.
  • Although controversial, the treatment of thyroid lymphoma is typically guided by the histologic subtype and extent of disease.
  • CLL/SLL is one of the rarest subtypes of lymphoma that can involve the thyroid gland.
  • Diagnosis of this entity is difficult, particularly before the recognition of systemic involvement, requiring the expertise of a multidisciplinary team for early detection and optimal management.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Thyroid Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718685.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD5
  •  go-up   go-down


60. Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE: The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer; 2010 May 1;116(9):2201-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.
  • BACKGROUND: Patients with recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) often have chemotherapy-resistant disease, resulting in poor prognosis.
  • An unanticipated finding in this study was an increase in absolute lymphocyte count (ALC) associated with a decrease in lymphadenopathy in 8 (36%) patients.
  • CONCLUSIONS: Everolimus has modest antitumor activity against CLL and can mobilize malignant cells from nodal masses into the peripheral circulation in a subset of CLL patients.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1325-30 [11571749.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):452-3 [12167696.001]
  • [Cites] Blood. 2003 Jan 1;101(1):278-85 [12393642.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):657-66 [14770419.001]
  • [Cites] Blood. 2004 May 1;103(9):3278-81 [14726385.001]
  • [Cites] Br J Haematol. 1996 Apr;93(1):151-3 [8611450.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):11-9 [15621776.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4070-8 [15767647.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5347-56 [15983389.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:292-8 [16304394.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):955-60 [16953237.001]
  • [Cites] Blood. 2007 Jan 15;109(2):405-11 [17008537.001]
  • [Cites] Leuk Res. 2007 Jul;31(7):899-906 [17241660.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):600-4 [17979945.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):508-14 [18543327.001]
  • [Cites] J Intern Med. 2008 Dec;264(6):549-62 [19017179.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2235-6 [19052968.001]
  • [Cites] Leuk Lymphoma. 2008 Dec;49(12):2333-43 [19052982.001]
  • [Cites] Ann Hematol. 2009 Mar;88(3):221-7 [18704419.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6680-6 [11426655.001]
  • (PMID = 20166206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097274-04; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / CA97274; United States / NCI NIH HHS / CA / P50 CA097274-04
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS189697; NLM/ PMC2861142
  •  go-up   go-down


61. Flanagan MB, Sathanoori M, Surti U, Soma L, Swerdlow SH: Cytogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic lymphocytic leukemia/small lymphocytic lymphoma lymphoid tissue biopsy specimens. Am J Clin Pathol; 2008 Oct;130(4):620-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic abnormalities detected by fluorescence in situ hybridization on paraffin-embedded chronic lymphocytic leukemia/small lymphocytic lymphoma lymphoid tissue biopsy specimens.
  • Cytogenetic fluorescence in situ hybridization (FISH) panels are a major prognostic tool in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but few data exist on using paraffin-embedded extramedullary tissue biopsy specimens for these purposes.
  • Isolated whole nuclei were extracted from 20 paraffin-embedded tissue biopsy specimens with CLL/SLL and analyzed using a standard CLL FISH panel.
  • Cytogenetic FISH studies using paraffin-embedded tissue biopsy specimens in CLL/SLL had a high yield and, with 1 exception, demonstrated a profile similar to cases diagnosed in PB/BM.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Paraffin Embedding

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794056.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Qi RJ, Zhang PH, Qiu LG, Fang LH, Yang QY, Sun FJ, Chen HS: [Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 May;38(5):329-32
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma].
  • OBJECTIVE: To study the clinicopathologic features and prognostic significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • METHODS: The histologic features of 52 cases of CLL/SLL with lymph node and/or bone marrow biopsies performed were retrospectively reviewed.
  • RESULTS: The lymph nodes of the 12 cases studied showed effacement of the nodal architecture and was replaced by a monotonous infiltration of small lymphoid cells.
  • Similar morphologic pattern was seen in the 40 bone marrow biopsy samples, but no proliferation center formation obtained.
  • The infiltration pattern of tumor cells in the bone marrow were further subdivided into nodular (n = 9), interstitial (n = 3), mixed (n = 9) and diffuse types (n = 19).
  • There was no significant difference found on survival rates between the diffuse infiltration and non-diffuse infiltration groups (Fisher's exact test, P = 0.199).
  • ZAP-70 protein was mainly located in the cytoplasm and nuclei of lymphoma cells.
  • Among the 21 dead cases, 15 died of CLL/SLL or the related infection.
  • CONCLUSION: A positive expression of ZAP-70 protein in CLL/SLL suggests a poor prognosis.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymph Nodes / pathology. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575876.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 2.7.10.2 / ZAP70 protein, human
  •  go-up   go-down


63. Garcia CF, Hunt KE, Kang H, Babb A, Gale JM, Vasef MA, Reichard KK: Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):119-27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status.
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is common in the Western world.
  • Genetic abnormalities detected by fluorescence in situ hybridization (FISH) and immunoglobulin heavy chain variable gene region (IGHV) mutational status are well-known independent prognostic indicators in CLL/SLL.
  • Given the requirement for specialized testing to detect such aberrations, we investigated whether morphologic features may predict the presence of a more or less favorable genetic profile.
  • Forty-one SLL cases were morphologically evaluated for expanded proliferation centers, increased large cells outside of proliferation centers, and nuclear contour irregularities (NCI) in small and large tumor cells.
  • Significant NCI in both small and large cells correlated with the presence of an unfavorable FISH abnormality (ie, ATM or p53 deletions).
  • No other significant associations with morphologic features were identified.
  • In conclusion, morphologic features in SLL are not a reliable predictor of underlying genetic status.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19826250.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IGH-CCND1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Tumor Suppressor Protein p53; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


64. Almhanna K, Wongchaowart N, Sweetenham J: Intracerebral Hodgkin's lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest; 2009 Feb;27(2):215-20
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracerebral Hodgkin's lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review.
  • Richter's syndrome is defined as the transformation of low grade lymphoma to more aggressive high grade malignant form, usually diffuse large B cell lymphoma.
  • Primary or metastatic cerebral Hodgkin's lymphoma and Hodgkin's lymphoma variant of Richter transformation are extremely rare.
  • We report a case of 65-year old man who developed isolated intracerebral Hodgkin's lymphoma almost 8 years after the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma, and we reviewed the related literature.
  • [MeSH-major] Brain Neoplasms / therapy. Hodgkin Disease / therapy. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Neoplasms, Second Primary / therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235595.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


65. Foo WC, Huang Q, Sebastian S, Hutchinson CB, Burchette J, Wang E: Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus. Hum Pathol; 2010 Dec;41(12):1802-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
  • A small fraction of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma develop Epstein-Barr virus-positive B-cell lymphoproliferative disorders.
  • These Epstein-Barr virus-B-cell lymphoproliferative disorders are thought to be related to immune suppression induced by fludarabine/other chemotherapeutic regimens.
  • As in other immunodeficiency-associated lymphoproliferative disorders, these disorders demonstrate a heterogeneous histological spectrum that ranges from polymorphic to monomorphic to classical Hodgkin lymphoma-like lesions.
  • We report a case of concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine.
  • Both classical Hodgkin lymphoma and plasmablastic lymphoma were positive for Epstein-Barr virus-encoded RNA, whereas classical Hodgkin lymphoma was also positive for Epstein-Barr virus- latent membrane protein 1, suggesting a different viral latency.
  • Immunoglobulin gene rearrangement studies demonstrated distinct clones in the plasmablastic lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • These findings suggest biclonal secondary lymphomas associated with iatrogenic immunodeficiency.
  • Epstein-Barr virus-B-cell lymphoproliferative disorders in the setting of chronic lymphocytic leukemia/small lymphocytic lymphoma, in particular those arising after chemotherapy, should be separated from true Richter's transformation, and be categorized as (iatrogenic) immunodeficiency-associated lymphoproliferative disorder.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Transformation, Neoplastic. Epstein-Barr Virus Infections / pathology. Lymphoproliferative Disorders / pathology. Vidarabine / analogs & derivatives
  • [MeSH-minor] Aged. B-Lymphocytes / pathology. Clone Cells. Fatal Outcome. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / drug therapy. Hodgkin Disease / pathology. Hodgkin Disease / virology. Humans. Immunocompromised Host. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Leukemia, Lymphocytic, Chronic, B-Cell / virology. Lymphoma, Large-Cell, Immunoblastic / drug therapy. Lymphoma, Large-Cell, Immunoblastic / pathology. Lymphoma, Large-Cell, Immunoblastic / virology. Male. Neoplasms, Multiple Primary. Plasma Cells / pathology


66. Sabattini E, Orduz R, Campidelli C, Zinzani PL, Callea V, Zupo S, Cutrona G, Morabito F, Ferrarini M, Pileri S: B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. J Clin Pathol; 2007 Jun;60(6):627-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.
  • BACKGROUND: The course of chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) partly depends on the mutational status of the variable region of immunoglobulin heavy chain genes (IgV(H)), which defines two subgroups of tumours: mutated and unmutated.
  • METHODS: 26 patients with CLL/SLL detected on BMB and with known IgV(H) mutational status were selected.
  • ZAP70 was determined by immunohistochemistry (IHC) comparing three antibodies from different sources (Upstate, Cell Signaling, Santa Cruz, California, USA) and two different methods (APAAP and EnVision(+)).
  • RESULTS: ZAP70 determination on BMB specimens turned out to be easily feasible with routine procedures with reagents from Upstate and Cell Signaling.
  • CONCLUSIONS: The study confirms the role of ZAP70 as a possible surrogate of mutational status and emphasises its application in routine diagnostics; it discloses a small subset of discordant cases (mutated/ZAP70 weakly positive) that clinically cluster with the more favourable forms.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. ZAP-70 Protein-Tyrosine Kinase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] Am J Clin Pathol. 1996 Oct;106(4):457-61 [8853032.001]
  • [Cites] Blood. 2001 Jul 1;98(1):181-6 [11418478.001]
  • [Cites] Leuk Res. 2001 Nov;25(11):927-32 [11597727.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2633-9 [11675331.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1625-38 [11733577.001]
  • [Cites] J Exp Med. 2001 Dec 3;194(11):1639-47 [11733578.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1023-9 [11807008.001]
  • [Cites] Br J Haematol. 2002 Jan;116(1):142-50 [11841407.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2262-4 [11877310.001]
  • [Cites] Ann Hematol. 2002 Jun;81(6):299-303 [12107557.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1410-6 [12149225.001]
  • [Cites] Eur J Haematol. 2003 Jan;70(1):53-9 [12631259.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1764-75 [12724482.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:153-75 [14633781.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):105-11 [14726163.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):455-62 [15160906.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):954-61 [15133473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):69-72 [15325098.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):795-805, vii [15325699.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):807-26, viii [15325700.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Aug;18(4):827-48, viii [15325701.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):893-901 [15329427.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2037-45 [15370248.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] J Clin Invest. 1998 Oct 15;102(8):1515-25 [9788964.001]
  • [Cites] J Clin Pathol. 1998 Jul;51(7):506-11 [9797726.001]
  • [Cites] Br J Haematol. 1999 May;105(2):394-401 [10233410.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1840-7 [10477712.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1848-54 [10477713.001]
  • [Cites] J Pathol. 2005 Mar;205(4):507-13 [15685592.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):755-64 [15711642.001]
  • [Cites] Leukemia. 2005 May;19(5):750-8 [15759031.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1018-24 [15800671.001]
  • [Cites] Cell. 1992 Nov 13;71(4):649-62 [1423621.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] N Engl J Med. 2000 Dec 28;343(26):1910-6 [11136261.001]
  • (PMID = 16916999.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Variable Region; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  • [Other-IDs] NLM/ PMC1955054
  •  go-up   go-down


67. Poterucha JT, Westberg M, Nerheim P, Lovell JP: Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J; 2010;37(2):218-20
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-CD20 monoclonal antibody rituximab is an effective treatment for small lymphocytic lymphoma; however, it has been associated with infusion reactions, including cardiac arrhythmias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Croat Med J. 2005 Dec;46(6):929-35 [16342346.001]
  • [Cites] Lancet. 1999 Nov 6;354(9190):1625-33 [10560690.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):317-24 [10637245.001]
  • [Cites] Cardiology. 2006;105(3):184-7 [16490965.001]
  • [Cites] Europace. 2006 Nov;8(11):1002-10 [17043073.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(4):465-71 [10855789.001]
  • [Cites] Med Clin North Am. 2001 Mar;85(2):321-41 [11233951.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):317-8 [15795913.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] Arch Mal Coeur Vaiss. 1966 Feb;59(2):263-72 [4956181.001]
  • [Cites] JAMA. 1993 Dec 1;270(21):2590-7 [8230644.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] J Am Coll Cardiol. 2002 Jul 3;40(1):105-10 [12103263.001]
  • (PMID = 20401299.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2851419
  • [Keywords] NOTNLM ; Antibodies, monoclonal/administration & dosage/adverse effects / cardiac pacing, artificial / electrocardiography / heart rate / long QT syndrome/diagnosis/etiology / lymphoma, B-cell/drug therapy / rituximab / tachycardia, ventricular/chemically induced/mortality / tachycardia/diagnosis / torsades de pointes/diagnosis/etiology
  •  go-up   go-down


68. O'Malley DP, Vance GH, Orazi A: Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall. Arch Pathol Lab Med; 2005 Jan;129(1):92-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic lymphocytic leukemia/small lymphocytic lymphoma with trisomy 12 and focal cyclin d1 expression: a potential diagnostic pitfall.
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma usually are distinctly different in regard to clinical presentation, morphology, immunophenotype, and molecular/genetic findings.
  • Cyclin D1 immunohistochemical staining is usually envisioned as a definitive method for resolving this differential diagnosis, with positivity supporting a diagnosis of mantle cell lymphoma.
  • We report a case involving a 58-year-old man with a diagnosis of CLL/SLL for several years.
  • A lymph node excision was performed after increased adenopathy was noted in the cervical region.
  • The excised lymph node showed typical morphologic findings of CLL/SLL, including the presence of characteristic proliferation centers.
  • Fluorescence in situ hybridization and conventional cytogenetics demonstrated trisomy 12 and an absence of t(11;14) in lymph node tissue.
  • Focal cyclin D1 expression by immunohistochemistry in nodal CLL/SLL is quite unusual and is discussed as a potential diagnostic pitfall.
  • [MeSH-major] Chromosomes, Human, Pair 12 / genetics. Cyclin D1 / biosynthesis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma, Mantle-Cell / diagnosis. Trisomy / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunophenotyping / methods. Male. Middle Aged

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15628916.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1
  •  go-up   go-down


69. Becker DJ, Sevilla DW, O'Connor O: Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus. Acta Haematol; 2010;123(2):77-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent and apposed hepatocellular carcinoma and small lymphocytic lymphoma/chronic lymphocytic leukemia in a patient with hepatitis C virus.
  • A patient with chronic hepatitis C virus (HCV) presented to our clinic with a hepatic mass as well as lymphocytosis.
  • Biopsy of the hepatic mass revealed apposed hepatocellular carcinoma (HCC) and small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL).
  • Dramatic examples of lymphoma regression during treatment with antiviral medication in chronic HCV patients have suggested an etiologic role for HCV in lymphomagenesis.
  • A growing body of research seeks to clarify the details of the interaction between HCV and B-cell lymphomas.
  • This case of adjacent SLL/CLL and HCC is the first published diagnosis of these two diseases in the liver at one time, and the only published example of the physical apposition of any lymphoma and HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / virology. Leukemia, Lymphocytic, Chronic, B-Cell / virology. Liver Neoplasms / virology
  • [MeSH-minor] Aged. Hepatitis C, Chronic / complications. Hepatitis C, Chronic / diagnosis. Humans. Male

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 20029171.001).
  • [ISSN] 1421-9662
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


70. Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ: Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol; 2009 Feb 20;27(6):904-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.
  • PURPOSE: Other malignancies have been reported to occur with increased frequency in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
  • The aim of this study was to determine the frequency, outcomes, and factors associated with other cancers in patients with CLL/SLL.
  • PATIENTS AND METHODS: We reviewed the records of consecutive patients with previously untreated CLL/SLL seen at The University of Texas M. D.
  • Overall, 625 cancers were observed in 551 patients, including skin (30%), prostate (13%), breast (9%), melanoma (8%), lymphoma (8%), gastrointestinal (9%), lung (6%), and other cancers (17%).
  • In Cox analysis, independent factors predicting development of new cancers were older age, male sex, and elevated levels of beta2-microglobulin, lactate dehydrogenase, and creatinine.
  • In patients who were treated for CLL/SLL, the treatment regimen did not affect the risk of subsequent cancer (P = .49).
  • CONCLUSION: Patients with CLL/SLL have more than twice the risk of developing a second cancer and an increased frequency of certain cancer types.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology. Neoplasms, Second Primary / epidemiology

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Blood. 1993 Jun 1;81(11):2878-84 [8499626.001]
  • [Cites] Leuk Res. 2005 Oct;29(10):1103-4 [16111529.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [8614005.001]
  • [Cites] Ann Hematol. 2004 Jun;83(6):356-63 [15024607.001]
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Clin Oncol. 2007 Oct 10;25(29):4648-56 [17925562.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2583-91 [15197800.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4079-88 [15767648.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):44-9 [1702145.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1414-20 [11230486.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] Semin Oncol. 2000 Dec;27(6 Suppl 12):37-41 [11225999.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [16391368.001]
  • [Cites] Blood. 1993 Sep 15;82(6):1695-700 [8400226.001]
  • (PMID = 19114699.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC4979239
  •  go-up   go-down


71. diSibio G, Gabor EP, Lopategui J, Sabath DE, Alsabeh R, Cole JM: Large-cell transformation of a composite lymphoma. Exp Mol Pathol; 2010 Dec;89(3):260-7
Genetic Alliance. consumer health - Lymphoma, large-cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-cell transformation of a composite lymphoma.
  • Composite lymphoma is a rarely reported entity, defined as two or more morphologically distinct types of lymphoma at the same anatomic site, occurring either synchronously or metachronously.
  • Since 1978, about 100 case reports of composite lymphoma have been cited, many involving combinations of low-grade B-cell lymphomas.
  • To our knowledge, no cases of large-cell transformation of composite lymphoma have yet been described.
  • We report the case of a patient who presented with diffuse large B-cell lymphoma (DLBCL) fifteen years after successful treatment for a mature B-cell lymphoma.
  • Reassessment of the patient's lymph node from 1995, using techniques not previously available, resulted in a revised diagnosis of composite lymphoma, comprising both follicular lymphoma (FL) and small lymphocytic lymphoma (SLL).
  • Analysis of B-cell gene rearrangement studies using BIOMED-2-based PCR, and of t(14;18) rearrangements by both FISH and PCR, provided evidence that the DLBCL evolved from transformation of the composite lymphoma, specifically from its FL component.
  • B-cell gene rearrangement studies also supported a clonal relationship between the FL and SLL components of the composite lymphoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Gene Rearrangement, B-Lymphocyte / genetics. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20621095.001).
  • [ISSN] 1096-0945
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Kalyan K, Basu D, Soundararaghavan J: Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification. Indian J Pathol Microbiol; 2006 Apr;49(2):203-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical typing of non-Hodgkin's lymphoma-comparing working formulation and WHO classification.
  • The recent WHO classification of non-Hodgkin's lymphoma is based on the morphology and immunohistochemical expression of the lymphoma cells and to a lesser extent, on the molecular and cytogenetic findings.
  • Fifty-three cases of non-Hodgkin's lymphoma were included in the study.
  • Of these, seven cases were primary extra nodal lymphomas.
  • The two most common types encountered were diffuse large cell lymphoma and small lymphocytic lymphoma.
  • 38 cases (72%) showed B cell expression and 12 cases (22.5%) showed T cell expression.
  • B-cell diffuse large cell lymphoma (26%) was found to be the predominant B cell non-Hodgkin's lymphoma.
  • The commonest T-cell lymphoma was T lymphoblastic lymphoma (67%) followed by peripheral T cell angioimmunoblastic lymphoma (25%).
  • Immunohistochemistry is a useful and necessary diagnostic modality and helps subdivide prognostically different types of non-Hodgkin's lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD20 / metabolism. Antigens, CD3 / metabolism. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. T-Lymphocytes / immunology. T-Lymphocytes / pathology. World Health Organization

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933715.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  •  go-up   go-down


73. Wang X, Asplund AC, Porwit A, Flygare J, Smith CI, Christensson B, Sander B: The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol; 2008 Oct;143(2):248-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival.
  • Gene expression analysis demonstrated high expression of the neuronal transcription factor SOX11 in mantle cell lymphoma (MCL).
  • In contrast to follicular lymphoma, small lymphocytic lymphoma and reactive lymphoid tissue, most MCLs tested (48/53 patients) expressed sox11 protein in the nucleus.
  • These results suggest sox11 expression as a new diagnostic marker in MCL that could be related to the clinical and biological behaviour of MCL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Gene Expression Regulation, Neoplastic. Lymphoma, Mantle-Cell / diagnosis. SOXC Transcription Factors / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Nucleus / chemistry. Cyclin D1 / genetics. Cytoplasm / chemistry. Female. Gene Expression. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Survival Rate

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18729857.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SOX11 protein, human; 0 / SOXC Transcription Factors; 136601-57-5 / Cyclin D1
  •  go-up   go-down


74. Bairey O, Shaklai M: Serum CA 125 levels in patients with chronic lymphocytic leukemia. Clin Lab Haematol; 2005 Feb;27(1):57-60
Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum CA 125 levels in patients with chronic lymphocytic leukemia.
  • Cancer antigen 125 (CA 125) is a glycoprotein expressed in normal tissues originally derived from celomic epithelia and its serum level is elevated in various benign and malignant conditions that involve stimulation of these tissues.
  • Elevated levels have been reported in 40-43% of patients with non-Hodgkin's lymphoma (NHL) at diagnosis and were associated with parameters known to be associated with advanced and disseminated disease, and with event-free and overall survival.
  • No difference in CA 125 level was found between indolent and aggressive lymphomas, and four of six patients with small lymphocytic lymphoma had elevated CA 125 levels.
  • We therefore decided to measure serum CA 125 levels in chronic lymphocytic leukemia (CLL) patients, and evaluated them in 74 consecutive patients.
  • The mean time from diagnosis to test was 74.5 months (range: 0-300).
  • The mean serum CA 125 level was 16.3 U/ml (range: 3.7-133, normal value: <35 U/ml).
  • CA 125 levels were elevated only in two patients (2.7%).
  • To conclude, serum CA 125 levels are rarely elevated in CLL patients.
  • It is possible that serum CA 125 levels can help differentiate between equivocal cases of small lymphocytic lymphoma and CLL.
  • [MeSH-major] CA-125 Antigen / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques / methods. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686509.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


75. Ertekin V, Orbak Z, Selimoglu MA, Yildiz L: Serum leptin levels in childhood celiac disease. J Clin Gastroenterol; 2006 Nov-Dec;40(10):906-9
Hazardous Substances Data Bank. GLUTEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in childhood celiac disease.
  • OBJECTIVE: Leptin has effects on growth and is also involved in immune regulation.
  • We thought that with its intestinal histopathologic alterations due to immune mechanisms, and subsequent malnutrition and/or growth failure, celiac disease (CD) deserves interest regarding leptin status.
  • METHOD: Serum leptin levels of 19 children with CD on admission and 1 year after gluten-free diet (GFD) and of 16 healthy children were determined.
  • Mean serum leptin level of children with CD on admission and of healthy children were 1.60+/-0.63 ng/mL, and 3.98+/-1.49 ng/mL, respectively (P: 0.0001).
  • Mean serum leptin level under GFD was 4.55+/-1.97 ng/mL.
  • There was a statistical significant difference between serum levels determined before and 1 year after GFD (P: 0.001) and between those of under GFD and healthy children (P: 0.001).
  • Mean serum leptin level of children with Marsh IIIc and Marsh IIIa were not different (1.70+/-0.73 ng/mL vs. 1.45+/-0.59 ng/mL).
  • Leptin was correlated with body mass index in healthy children, and in CD both before and after GFD (P<0.001).
  • Serum leptin level was not correlated with lumbar z score either before or after GFD.
  • CONCLUSIONS: Serum leptin level is affected in childhood CD, it is not directly related to histopathologic findings, and is responsive to GFD.
  • Further studies investigating its level in different clinical and histopathologic presentations might give clear clues about the role of leptin in CD.
  • [MeSH-major] Celiac Disease / blood. Leptin / blood

  • Genetic Alliance. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063109.001).
  • [ISSN] 0192-0790
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin; 8002-80-0 / Glutens
  •  go-up   go-down


76. Kiselow MA, Rassnick KM, McDonough SP, Goldstein RE, Simpson KW, Weinkle TK, Erb HN: Outcome of cats with low-grade lymphocytic lymphoma: 41 cases (1995-2005). J Am Vet Med Assoc; 2008 Feb 1;232(3):405-10
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of cats with low-grade lymphocytic lymphoma: 41 cases (1995-2005).
  • OBJECTIVE: To evaluate factors associated with response to treatment, remission duration, and survival in cats with low-grade lymphoma affecting various organ systems.
  • SAMPLE POPULATION: 41 cats with histologically confirmed low-grade lymphocytic lymphoma.
  • PROCEDURES: Medical records and biopsy specimens of cats with histologically confirmed low-grade lymphocytic lymphoma of various organ systems treated with prednisone and chlorambucil between 1995 and 2005 were reviewed.
  • Seventy-eight percent of cats tested had low serum cobalamin concentrations.
  • Lymphoma was confined to the gastrointestinal tract in 68% of cats.
  • CONCLUSIONS AND CLINICAL RELEVANCE: Most cats with lymphocytic lymphoma responded to treatment with prednisone and chlorambucil, and most factors evaluated were not associated with outcome.
  • [MeSH-major] Cat Diseases / drug therapy. Chlorambucil / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / veterinary. Prednisone / therapeutic use. Remission Induction

  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241108.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 18D0SL7309 / Chlorambucil; VB0R961HZT / Prednisone
  •  go-up   go-down


77. Unal M, Eskandari G, Muşlu N, Pata YS, Akbaş Y: Serum leptin levels in patients with allergic rhinitis. Otolaryngol Head Neck Surg; 2006 Feb;134(2):331-3
Genetic Alliance. consumer health - Allergic rhinitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in patients with allergic rhinitis.
  • OBJECTIVE: To investigate the serum leptin levels in patients with allergic rhinitis during the symptomatic period.
  • RESULTS: Leptin levels were 28.8 +/- 14.1 ng/mL in the patients with allergic rhinitis, and 20.8 +/- 13.5 ng/mL in the control group respectively.
  • CONCLUSION: Serum leptin levels were found to be significantly higher in patients with allergic rhinitis in symptomatic period.
  • SIGNIFICANCE: Apart from its primary role in the regulation of body weight and energy expenditure, leptin may have a role in the inflammatory process of the allergic rhinitis.
  • [MeSH-major] Leptin / blood. Rhinitis / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455387.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


78. Atmaca M, Tezcan E, Kuloglu M, Ustundag B: Serum leptin levels in obsessive-compulsive disorder. Psychiatry Clin Neurosci; 2005 Apr;59(2):189-93
Hazardous Substances Data Bank. HYDROCORTISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in obsessive-compulsive disorder.
  • The aim of the present study was to evaluate serum leptin levels to demonstrate whether or not its eventual alterations might have an etiopathogenetic significance in patients with obsessive-compulsive disorder (OCD).
  • Thus, it was planned to examine whether serum leptin levels were affected by pure OCD (OCD-D), pure depression (D) or the comorbidity of OCD and depression (OCD+D).
  • Forty-four patients with OCD (27 with OCD-D and 17 with OCD+D), 38 depressed patients and 30 control subjects were enrolled and serum leptin and cortisol levels were measured.
  • According to the mean leptin levels, no significant difference was found between the OCD-D and control groups and between the OCD+D and D groups, while statistically significantly lower levels were found in the OCD+D and D groups than in control group.
  • Significant difference in the mean leptin levels was found among groups even after controlling for body mass index or sex.
  • The present study confirms the strong relationship between serum leptin and cortisol values and suggests that reduced leptin levels, rather than having an etiopathogenetic significance in patients with OCD, seem to be associated with patients with OCD and depression but not with pure OCD patients, and that OCD may be a heterogeneous subtype containing some biological indications of anxiety and affective disorders.
  • [MeSH-major] Leptin / blood. Obsessive-Compulsive Disorder / blood
  • [MeSH-minor] Adolescent. Adult. Depressive Disorder / blood. Depressive Disorder / complications. Female. Humans. Hydrocortisone / blood. Male. Middle Aged. Reference Values

  • Genetic Alliance. consumer health - Obsessive Compulsive Disorder.
  • MedlinePlus Health Information. consumer health - Obsessive-Compulsive Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823166.001).
  • [ISSN] 1323-1316
  • [Journal-full-title] Psychiatry and clinical neurosciences
  • [ISO-abbreviation] Psychiatry Clin. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Leptin; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


79. Baig M, Azhar A, Zaidi P, Kamal S, Karira K: Serum leptin level in hypothyroid males. J Coll Physicians Surg Pak; 2005 Dec;15(12):757-60
MedlinePlus Health Information. consumer health - Hypothyroidism.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin level in hypothyroid males.
  • OBJECTIVE: To determine the correlation of serum leptin with thyroid hormones in primary hypothyroid male patients and euthyroid lean and obese control subjects.
  • Serum leptin was measured by ELISA and FT4, FT3 and TSH were measured by radioimmunoassay (RIA), triacylglycerol (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C) by kit method, low density lipoprotein cholesterol (LDL-C) was calculated by the Friedwald s formula, and fasting blood sugar (FBS) by glucose oxidase method.
  • RESULTS: The mean +/- SEM values of leptin in male hypothyroid patients were 10.71+/-2.5 ng/ml, 8.27+/-1.91 in control group and 21.34+/-3.4 ng/ml in obese group, respectively.
  • No significant difference was found in serum leptin levels between hypothyroid patients and their age, BMI matched control group, while obese control group had significantly higher values of leptin (<0.05).
  • There was no significant correlation of leptin found with T4, T3, and TSH in hypothyroid patients and lean and obese control subjects.
  • This study observed that serum leptin level was significantly correlated with the BMI (r = 0.732, p < 0.005, r = 0.783, p < 0.005, r = 0.653, p < 0.005), in normal lean, obese and hypothyroid male patients respectively.
  • CONCLUSION: The results of this study suggest that there is no correlation between serum leptin and thyroid hormones in hypothyroid patients as well as in euthyroid subjects.
  • Serum leptin is directly related with BMI.
  • [MeSH-major] Hypothyroidism / blood. Leptin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16398964.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Leptin; 0 / Thyroid Hormones
  •  go-up   go-down


80. Aliustaoglu M, Bilici A, Gumus M, Colak AT, Baloglu G, Irmak R, Seker M, Ustaalioglu BB, Salman T, Sonmez B, Salepci T, Yaylaci M: Preoperative serum leptin levels in patients with breast cancer. Med Oncol; 2010 Jun;27(2):388-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative serum leptin levels in patients with breast cancer.
  • Leptin is an adipocyte-derived protein and plays an important role in the control of body weight by acting as a neurohormone regulating energy balance and food intake in the hypothalamus.
  • The high serum leptin levels and the overexpression of leptin receptors have been documented in breast cancer patients, but the levels never checked preoperatively.
  • In the present study, the relationship between preoperative serum leptin levels of the breast cancer patients and the healthy controls were evaluated.
  • The serum leptin levels in 30 breast cancer patients were compared to 30 healthy female volunteers.
  • In addition, the association of serum leptin levels and the various well-known risk factors were studied.
  • Serum leptin levels of patients with breast cancer (28.55 + 19.7 ng/ml) were tended to be higher than those of controls (26.43 + 19.4 ng/ml), but it did not reach statistical difference (P = 0.712).
  • There was significant correlation between the expression of ER, PR, and serum leptin levels (P = 0.018 and 0.037, respectively), but not with the HER-2/neu receptor expression (P = 0.067).
  • Also association was not found between the tumor size, lymph node involvement, and the levels of serum leptin (P = 0.235, 0.34, and 0.86, respectively).
  • The serum leptin level was also found to be similar in premenopausal (24.85 +/- 18.14 ng/ml) and postmenopausal (30.49 +/- 17.19 ng/ml) patients (P = 0.235).
  • The preoperative serum leptin levels in breast cancer patients were similar to healthy controls.
  • In subset analysis, the significant correlation between the leptin level and hormonal status was noted, but association with HER-2/neu was not detected.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / surgery. Leptin / blood. Preoperative Care

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 1996 Apr;137(4):1501-4 [8625930.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):425-32 [7984236.001]
  • [Cites] Clin Chim Acta. 2003 Aug;334(1-2):137-44 [12867284.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1341-5 [11238530.001]
  • [Cites] N Engl J Med. 1996 Feb 1;334(5):292-5 [8532024.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1683-6 [9733517.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6365-78 [15322511.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):523-6 [9935151.001]
  • [Cites] Int J Mol Med. 2000 Apr;5(4):421-6 [10719061.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4325-31 [15240518.001]
  • [Cites] Nature. 1996 Apr 25;380(6576):677 [8614460.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1414-9 [16206269.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] J Cell Physiol. 2006 Apr;207(1):12-22 [16110483.001]
  • [Cites] J Nutr. 1997 May;127(5 Suppl):921S-923S [9164264.001]
  • [Cites] Maturitas. 2000 May 29;35(2):175-9 [10924844.001]
  • [Cites] Nature. 2001 May 17;411(6835):390-5 [11357148.001]
  • [Cites] Epidemiology. 1995 Mar;6(2):137-41 [7742399.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1529-35 [15138597.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1668-76 [10029596.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):49-66 [12160086.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):424-7 [11689595.001]
  • [Cites] Fertil Steril. 2000 Mar;73(3):493-8 [10689001.001]
  • [Cites] J Clin Invest. 1996 Sep 15;98(6):1277-82 [8823291.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3244-8 [12947058.001]
  • [Cites] Clin Sci (Lond). 1997 Sep;93(3):273-7 [9337643.001]
  • (PMID = 19412673.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


81. Klabusay M, Sukova V, Coupek P, Brychtova Y, Mayer J: Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases. Cytometry B Clin Cytom; 2007 Sep;72(5):363-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
  • BACKGROUND: The success of treatment using monoclonal antibodies in oncology is influenced by, among other factors, the level of target antigen expression on tumor cells.
  • The authors analyzed the intensity of the CD52 antigen expression in patients with chronic lymphoproliferative diseases and compared them with B-lymphocytes of a healthy population and CD34(+) cells in peripheral blood stem cells (PBSC) grafts.
  • METHODS: Recently diagnosed and previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL), mantle-cell lymphoma (MCL), or small lymphocytic lymphoma (SLL) were evaluated and compared with control group and CD34(+) cells.
  • RESULTS: In the group of patients with B-CLL, the CD52 level on tumor cells (245 x 10(3) MESF; 107 x 10(3) ABC) was significantly lower than on B-lymphocytes of the control group (446 x 10(3) MESF; 194 x 10(3) ABC; P < 0.001) and SLL tumor cells (526 x 10(3) MESF; 229 x 10(3) ABC; P < 0.001).
  • CONCLUSIONS: Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells.
  • CD52 antigen is expressed at low level on CD34(+) cells.
  • [MeSH-major] Antigens, CD / analysis. Antigens, CD34 / biosynthesis. Antigens, Neoplasm / analysis. B-Lymphocytes / immunology. Flow Cytometry / methods. Glycoproteins / analysis. Hematopoietic Stem Cells / immunology. Lymphoproliferative Disorders / diagnosis. Lymphoproliferative Disorders / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Biomarkers / analysis. Biomarkers, Tumor / analysis. Biomarkers, Tumor / immunology. Chronic Disease. Female. Humans. Leukemia, B-Cell / blood. Leukemia, B-Cell / diagnosis. Leukemia, B-Cell / immunology. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Lymphocyte Activation / immunology. Lymphoma, Mantle-Cell / blood. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / immunology. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Clinical Cytometry Society.
  • (PMID = 17428002.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


82. Guven M, Bulut Y, Aladag I, Yelken K, Erdoğan H: Serum leptin levels in patients with nasal polyposis. J Laryngol Otol; 2008 Jun;122(6):590-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in patients with nasal polyposis.
  • OBJECTIVES: The aim of this study was to investigate the serum leptin levels in patients with nasal polyposis.
  • RESULTS: Serum leptin levels were 12.10 +/- 9.39 ng/ml in the nasal polyposis patients and 6.17 +/- 7.68 ng/ml in the controls.
  • A significant difference (p = 0.021) was observed in the mean serum leptin levels between nasal polyposis patients and controls.
  • CONCLUSION: Serum leptin levels were found to be significantly higher in patients with nasal polyposis.
  • Leptin, apart from its primary role in the regulation of body weight and energy expenditure, may have a role in the inflammatory response of nasal polyposis.
  • [MeSH-major] Leptin / blood. Nasal Polyps / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625035.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin
  •  go-up   go-down


83. Calka O, Metin A, Dülger H, Erkoç R: Effect of cyproheptadine on serum leptin levels. Adv Ther; 2005 Sep-Oct;22(5):424-8
Hazardous Substances Data Bank. CYPROHEPTADINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of cyproheptadine on serum leptin levels.
  • Leptin is a 167 amino acid protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism.
  • Although both leptin and cyproheptadine are effective in controlling appetite, their interaction has not been addressed in clinical studies.
  • This study evaluated serum leptin concentrations in patients who received cyproheptadine to treat a variety of disorders.
  • Serum leptin levels were determined by leptin radioimmunoassay.
  • The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean leptin level after 1 week of treatment with cyproheptadine (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05).
  • This increase may suggest that both leptin and cyproheptadine may affect appetite via similar receptors and that cyproheptadine does not impair leptin activity through these receptors.
  • [MeSH-major] Appetite Stimulants / pharmacology. Cyproheptadine / pharmacology. Leptin / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418149.001).
  • [ISSN] 0741-238X
  • [Journal-full-title] Advances in therapy
  • [ISO-abbreviation] Adv Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Appetite Stimulants; 0 / Leptin; 2YHB6175DO / Cyproheptadine
  •  go-up   go-down


84. Tsimberidou AM, Keating MJ, Wierda WG: Richter's transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep; 2007 Oct;2(4):265-71
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Richter's transformation in chronic lymphocytic leukemia.
  • Richter's syndrome (RS) is the development of high-grade non-Hodgkin's lymphoma (NHL) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma.
  • The large cells of RS either arise through a transformation of the original CLL clone or, less frequently, represent a new or secondary neoplasm.
  • Karyotypic changes, including trisomy 12, chromosome 11 abnormalities, and multiple cell-cycle regulator disruptions, have been found in patients with RS.
  • Rituximab and cytotoxic combination therapy followed by stem cell transplantation is associated with improved clinical outcome.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Lymphoma, Non-Hodgkin / etiology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Cycle Proteins / genetics. Cell Transformation, Viral. Chromosome Aberrations. Clinical Trials as Topic. Combined Modality Therapy. Disease Progression. Epstein-Barr Virus Infections / complications. Genes, Tumor Suppressor. Humans. Immunocompromised Host. Immunologic Factors / therapeutic use. Immunotherapy. Neoplasm Proteins / genetics. Prognosis. Rituximab. Stem Cell Transplantation. Tomography, Emission-Computed, Single-Photon

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] Blood. 1994 Mar 1;83(5):1363-72 [8118038.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2977-84 [9531609.001]
  • [Cites] Am J Hematol. 1999 Feb;60(2):99-104 [9929100.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):484-7 [12406089.001]
  • [Cites] Annu Rev Immunol. 2007;25:587-617 [17378764.001]
  • [Cites] Am J Clin Pathol. 1990 Mar;93(3):333-9 [1689938.001]
  • [Cites] Am J Med. 1980 Apr;68(4):539-48 [6989238.001]
  • [Cites] Am J Clin Pathol. 1990 Jan;93(1):117-23 [2294692.001]
  • [Cites] Blood. 1999 Jul 15;94(2):448-54 [10397712.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1302-8 [7023653.001]
  • [Cites] Cancer. 2006 Sep 15;107(6):1294-302 [16902984.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1757-61 [9473243.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1985-9 [8410123.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):235-42 [12950231.001]
  • [Cites] Ann Intern Med. 1993 Jul 1;119(1):63-73 [8498765.001]
  • [Cites] Cancer. 2004 May 15;100(10 ):2195-200 [15139064.001]
  • [Cites] Leukemia. 1992 Sep;6(9):902-6 [1387694.001]
  • [Cites] Leukemia. 2003 Feb;17 (2):411-5 [12592341.001]
  • [Cites] Blood. 1992 May 15;79(10):2701-7 [1375111.001]
  • [Cites] Adv Cancer Res. 1995;67:197-255 [8571815.001]
  • [Cites] Cancer. 1980 Jul 1;46(1):118-34 [6770990.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):767-72 [12153163.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):140-4 [2112977.001]
  • [Cites] Blood. 1984 Aug;64(2):571-5 [6331551.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):897-9 [11054078.001]
  • [Cites] Leukemia. 1991 Jun;5(6):522-7 [1711641.001]
  • [Cites] Blood. 1996 Mar 1;87(5):1900-11 [8634438.001]
  • [Cites] Cancer. 2003 Apr 1;97(7):1711-20 [12655528.001]
  • [Cites] Am J Surg Pathol. 1988 Dec;12(12):907-17 [3059831.001]
  • [Cites] Eur J Immunol. 1999 Apr;29(4):1253-64 [10229093.001]
  • [Cites] Mod Pathol. 2001 May;14(5):452-7 [11353056.001]
  • [Cites] Hum Pathol. 1990 Jul;21(7):722-8 [2361698.001]
  • [Cites] Leuk Lymphoma. 2006 May;47(5):827-36 [16753866.001]
  • [Cites] Am J Pathol. 1928 Jul;4(4):285-292.7 [19969796.001]
  • [Cites] Am J Clin Pathol. 1975 Jun;63(6):786-95 [1096589.001]
  • [Cites] Exp Hematol. 2004 Jan;32(1):28-35 [14725898.001]
  • [Cites] Blood. 1994 Aug 1;84(3):972-84 [8043879.001]
  • [Cites] Adv Immunol. 1985;37:99-149 [2988307.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):151-5 [10613460.001]
  • [Cites] Am J Clin Pathol. 1995 Aug;104(2):199-203 [7639196.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Mar;94(1):27-35 [9078288.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Oct 1;106(1):80-3 [9772916.001]
  • [Cites] Leuk Lymphoma. 2001 Jul;42(3):329-37 [11699397.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2343-51 [16710033.001]
  • [Cites] Am J Surg Pathol. 1992 Sep;16(9):859-67 [1384376.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1028-34 [12040434.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):251-9 [10439362.001]
  • [Cites] J Nucl Med. 2006 Aug;47(8):1267-73 [16883004.001]
  • (PMID = 20425379.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cell Cycle Proteins; 0 / Immunologic Factors; 0 / Neoplasm Proteins; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 54
  •  go-up   go-down


85. Ozkan S, Erel CT, Madazli R, Aydinli K: Serum leptin levels in hypertensive disorder of pregnancy. Eur J Obstet Gynecol Reprod Biol; 2005 Jun 1;120(2):158-63
MedlinePlus Health Information. consumer health - High Blood Pressure in Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in hypertensive disorder of pregnancy.
  • OBJECTIVE: To determine serum leptin levels in hypertensive disorder of pregnancy.
  • MATERIALS AND METHODS: In this prospective, cross-sectional, case control study, we measured serum leptin levels of 58 hypertensive pregnant women and 54 normal pregnant women.
  • We also did blood and urine analysis for the evaluation of the severity of hypertensive disorder of pregnancy.
  • We analysed the difference and correlation between anthropometric measures, hormonal and biochemical parameters, and serum leptin levels in two groups.
  • RESULTS: In the study group, serum leptin levels were determined to be higher than the control group.
  • While the serum uric acid, urea, aspartate aminotransferase, fibronectin, and fasting blood glucose levels were found to be higher, serum total protein and albumin levels were significantly lower among the hypertensive pregnant women.
  • Serum leptin levels were highly and positively correlated with serum fibronectin, and C peptide levels.
  • A negative significant correlation was observed between maternal serum leptin levels and neonatal birth weight among the pregnant women having the hypertensive disorders.
  • CONCLUSION: Serum leptin levels in hypertensive pregnant women appear to be higher.
  • The determination of serum leptin levels may be as important as serum fibronectin and C peptide levels in the management of hypertensive disorder of pregnancy.
  • C peptide and insulin may be due to hyperinsulinemia which leads to increased stimulation of leptin production by fatty tissue.
  • [MeSH-major] Hypertension, Pregnancy-Induced / blood. Leptin / blood

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925044.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / C-Peptide; 0 / Fibronectins; 0 / Leptin
  •  go-up   go-down


86. Dingiloglu BS, Gungor T, Ozdal B, Cavkaytar S, Bilge U, Mollamahmutoglu L: Serum leptin levels in women with uterine leiomyomas. Taiwan J Obstet Gynecol; 2007 Mar;46(1):33-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in women with uterine leiomyomas.
  • OBJECTIVE: The purpose of this study was to examine the influence of leptin in women with uterine myoma.
  • In all subjects, FSH, LH, E2, prolactin, hemoglobin, hematocrit, blood urea nitrogen, creatinine, fasting glucose, CA125, and leptin were examined, and body mass index (BMI) was calculated.
  • RESULTS: Although leptin level was higher in the myomatic women (5.73 +/- 4.08 ng/mL) than in the normal women, there was no statistically significant difference (p = 0.303).
  • Also, no statistical difference in the ratios of leptin/BMI was found in both groups.
  • A significant correlation was found between high E2 level and myoma uteri (p = 0.021).
  • Hemoglobin levels were significantly lower in the myomatic women (p = 0.044).
  • When we compared the leptin levels according to BMI, leptin levels were higher in patients who had BMI > 30 (p = 0.02).
  • CONCLUSION: We did not find any significant difference in serum leptin levels between the two groups.
  • But leptin may have an indirect role in the pathogenesis of uterine leiomyoma.
  • So further research is needed to reveal the role of leptin in myoma uteri pathogenesis.
  • [MeSH-major] Leiomyoma / blood. Leptin / blood. Uterine Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17389186.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Hemoglobins; 0 / Hormones; 0 / Leptin
  •  go-up   go-down


87. Pangalis GA, Kyrtsonis MC, Kontopidou FN, Siakantaris MP, Dimopoulou MN, Vassilakopoulos TP, Tzenou T, Kokoris S, Dimitriadou E, Kalpadakis C, Tsalimalma K, Tsaftaridis P, Panayiotidis P, Angelopoulou MK: Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders. Clin Lymphoma; 2005 Mar;5(4):235-40
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
  • Waldenstrom's macroglobulinemia (WM) is characterized by lymphoplasmacytic infiltration of bone marrow and/or other tissues and by the presence of serum monoclonal immunoglobulin M ([IgM], without cutoff limit).
  • Differential diagnosis from other B-cell disorders (BCDs) is usually easy based on clinical, morphologic, histopathologic, immunophenotypic, and genetic features.
  • Eighty-four patients were diagnosed with WM, 5 with IgM-monoclonal gammopathy of undetermined significance (MGUS), and 41 with other BCDs (9 with B-cell chronic lymphocytic leukemia, 5 with small lymphocytic lymphoma, 14 with marginal zone lymphoma, 5 with mantle-cell lymphoma, 2 with follicular lymphoma, 2 with diffuse large B-cell lymphoma, 2 with cryoglobulinemia, and 2 with low-grade lymphoma not otherwise specified).
  • Median IgM levels were 3215 mg/dL in WM, 840 mg/dL in IgM-MGUS, and 285 mg/dL in other BCDs (5 had IgM levels > 1500 mg/dL).
  • Forty-four percent of patients with BCDs (splenic marginal zone lymphoma or small lymphocytic lymphoma) had diagnoses that corresponded to that of WM.
  • Careful diagnosis requires the concomitant evaluation of all parameters of BCDs together.
  • Marginal zone lymphoma is the most frequently overlapping entity.
  • Special attention should be given to mantle cell lymphoma in its atypical forms.
  • [MeSH-major] Immunoglobulin M / analysis. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Lymphoma / diagnosis. Waldenstrom Macroglobulinemia / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Gene Expression Profiling. Humans. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / immunology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15794855.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin M
  •  go-up   go-down


88. Kojima M, Tsukamoto N, Yokohama A, Suzuki Y, Shimizu K, Nishikawa M, Murayama K, Miyanaga T, Isoda A, Shimizu K, Itoh H, Masawa N, Yoshida K, Inagaki H: B-cell lymphoma associated with Sjögren's syndrome among Japanese patients: a clinicopathologic and immunohistochemical study of 15 cases. J Clin Exp Hematop; 2009 Nov;49(2):89-95
MedlinePlus Health Information. consumer health - Sjogren's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma associated with Sjögren's syndrome among Japanese patients: a clinicopathologic and immunohistochemical study of 15 cases.
  • To clarify the clinicopathological findings of B-cell lymphoma associated with Sjögren's syndrome (SJS) among Japanese Patients, 15 individuals with this disease were studied.
  • These lymphomas arose not only in the salivary gland (n=4) but also in other mucosal extranodal sites (n=5).
  • Histologically, six cases were marginal zone B-cell lymphoma (MZBL) of the mucosa-associated lymphoid tissue (MALT) type, three cases were diffuse large B-cell lymphoma (DLBCL) + MALT type lymphoma, two cases were nodal MZBL and one case each was small lymphocytic lymphoma, Burkitt's lymphoma, CD10(+) DLBCL and DLBCL + nodal MZBL.
  • Using in situ hybridization, numerous Epstein-Barr virus(+) tumor cells were detected only in the case of Burkitt lymphoma.
  • There were no human-herpes type 8(+) tumor cells in any of the 15 cases.
  • B-cell lymphoma associated with SJS also frequently affected extranodal organs in patients from Japan as well as from patients in Western countries.
  • The majority of B-cell lymphomas in patients with SJS also appear to be low-grade MZBLs or high-grade lymphomas probably derived from MZBL both in Western countries and in Japan.
  • [MeSH-major] Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. Sjogren's Syndrome / metabolism. Sjogren's Syndrome / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19907113.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O: (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med; 2010 Jan;51(1):25-30
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients.
  • PET/CT with (18)F-FDG is an important noninvasive diagnostic tool for management of patients with lymphoma, and its use may surpass current guideline recommendations.
  • The aim of the present study is to enlarge the growing body of evidence concerning (18)F-FDG avidity of lymphoma to provide a basis for future guidelines.
  • METHODS: The reports from (18)F-FDG PET/CT studies performed in a single center for staging of 1,093 patients with newly diagnosed Hodgkin disease and non-Hodgkin lymphoma between 2001 and 2008 were reviewed for the presence of (18)F-FDG avidity.
  • Of these patients, 766 patients with a histopathologic diagnosis verified according to the World Health Organization classification were included in the final analysis. (18)F-FDG avidity was defined as the presence of at least 1 focus of (18)F-FDG uptake reported as a disease site.
  • RESULTS: At least one (18)F-FDG-avid lymphoma site was reported for 718 patient studies (94%).
  • Forty-eight patients (6%) had lymphoma not avid for (18)F-FDG. (18)F-FDG avidity was found in all patients (100%) with Hodgkin disease (n = 233), Burkitt lymphoma (n = 18), mantle cell lymphoma (n = 14), nodal marginal zone lymphoma (n = 8), and lymphoblastic lymphoma (n = 6).
  • An (18)F-FDG avidity of 97% was found in patients with diffuse large B-cell lymphoma (216/222), 95% for follicular lymphoma (133/140), 85% for T-cell lymphoma (34/40), 83% for small lymphocytic lymphoma (24/29), and 55% for extranodal marginal zone lymphoma (29/53).
  • CONCLUSION: The present study indicated that with the exception of extranodal marginal zone lymphoma and small lymphocytic lymphoma, most lymphoma subtypes have high (18)F-FDG avidity.
  • The cumulating evidence consistently showing high (18)F-FDG avidity in the potentially curable Burkitt, natural killer/T-cell, and anaplastic large T-cell lymphoma subtypes justifies further investigations of the utility of (18)F-FDG PET in these diseases at presentation.
  • [MeSH-major] Fluorodeoxyglucose F18 / pharmacokinetics. Lymphoma / metabolism. Lymphoma / radionuclide imaging. Radiopharmaceuticals / pharmacokinetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009002.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


90. Neuteboom RF, Verbraak E, Voerman JS, van Meurs M, Steegers EA, de Groot CJ, Laman JD, Hintzen RQ: Serum leptin levels during pregnancy in multiple sclerosis. Mult Scler; 2009 Aug;15(8):907-12
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels during pregnancy in multiple sclerosis.
  • Leptin has been identified as a hormone that can influence inflammatory activity.
  • OBJECTIVE: The aim of this study was to investigate whether pregnancy-induced fluctuations of serum leptin levels differed between patients with MS and controls and whether serum leptin levels correlate with periods of enhanced and diminished disease activity.
  • Serum leptin and soluble leptin receptor (SLR) levels were measured using enzyme-linked immunosorbent assay.
  • RESULTS: Pre-pregnancy serum leptin levels were (mean +/- SD) 22.9 +/- 12.8 ng/ml in the MS group.
  • These levels increased in the third trimester to 28.5 +/- 15.0 ng/ml (P = 0.007).
  • The third trimester serum leptin levels in healthy women were comparable, 29.4 +/- 19.0 ng/ml.
  • Serum leptin levels after delivery dropped to 18.5 +/- 12.8 ng/ml in women with MS (P < 0.001) and to a lesser extend (22.0 +/- 17.5 ng/ml) in healthy women (P = 0.04).
  • SLR levels showed the same pattern.
  • Remarkably, women with the highest relative decrease in serum leptin levels after delivery had more often a postpartum relapse (P = 0.008).
  • CONCLUSION: In women with MS, leptin increased during late pregnancy.
  • A postdelivery drop in leptin levels was observed in both the MS and control group.
  • [MeSH-major] Leptin / blood. Multiple Sclerosis / blood. Pregnancy Complications / blood
  • [MeSH-minor] Adult. Biomarkers / blood. Case-Control Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Postpartum Period / blood. Pregnancy. Pregnancy Trimesters / blood. Prospective Studies. Receptors, Leptin / blood. Recurrence. Young Adult

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667019.001).
  • [ISSN] 1352-4585
  • [Journal-full-title] Multiple sclerosis (Houndmills, Basingstoke, England)
  • [ISO-abbreviation] Mult. Scler.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin; 0 / Receptors, Leptin; 0 / leptin receptor, human
  •  go-up   go-down


91. Demir B, Guven S, Guven ES, Atamer Y, Gunalp GS, Gul T: Serum leptin level in women with unexplained infertility. J Reprod Immunol; 2007 Oct;75(2):145-9
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin level in women with unexplained infertility.
  • INTRODUCTION: The aim of this study was to compare serum levels of leptin in women with unexplained infertility with fertile subjects.
  • MATERIAL AND METHOD: Serum leptin levels of 27 infertile and 30 fertile women on day 3 of the menstrual cycle were assessed and compared in this prospective age and body mass index (BMI) comparable controlled study.
  • The mean serum leptin level was significantly higher in women with unexplained infertility compared with fertile subjects.
  • Considering normal weight subjects, mean serum leptin levels were increased significantly in the unexplained infertile group compared with the fertile group (7.2 (range, 4.3-10.4) versus 3.5 (range, 1.9-6.2)ng/ml, respectively; p<0.0001, Mann-Whitney U-test).
  • The significant increase in serum leptin levels was observed also in overweight patients (6.8 (range, 1.3-5.2) versus 3.3 (range, 4.2-8.9)ng/ml, respectively; p<0.0001, Mann-Whitney U-test).
  • CONCLUSION: A significant difference in serum leptin levels between unexplained infertile and fertile women suggests that this cytokine may be involved in pathophysiology of unexplained infertility.
  • [MeSH-major] Infertility, Female / etiology. Leptin / blood

  • Genetic Alliance. consumer health - infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17485120.001).
  • [ISSN] 0165-0378
  • [Journal-full-title] Journal of reproductive immunology
  • [ISO-abbreviation] J. Reprod. Immunol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


92. Peggs KS, Mackinnon S, Linch DC: The role of allogeneic transplantation in non-Hodgkin's lymphoma. Br J Haematol; 2005 Jan;128(2):153-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of allogeneic transplantation in non-Hodgkin's lymphoma.
  • The evolution of combination chemotherapy regimens, combined with improvements in supportive care, has incrementally improved survival outcomes for patients with non-Hodgkin's lymphomas (NHL).
  • Although 40-60% of younger patients with diffuse large cell lymphoma can now expect to be cured, significant numbers will either fail to achieve a remission or relapse after attaining a remission.
  • In addition, certain histological subtypes are associated with particularly poor prognoses with combination chemotherapy alone (e.g. mantle cell lymphoma, B-cell prolymphocytic leukaemia).
  • Other NHL subtypes, whilst associated with more favourable prognoses in terms of overall survival, are rarely, if ever, cured (e.g. most low grade NHL including follicular lymphoma, chronic lymphocytic leukaemia and small lymphocytic lymphoma).
  • The parallel development of transplantation approaches that limit procedural toxicity along with advances in supportive care require that the role of allogeneic haematopoietic stem cell transplantation in the management of lymphoma be re-evaluated.
  • [MeSH-major] Bone Marrow Transplantation. Lymphoma, Non-Hodgkin / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15638849.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 79
  •  go-up   go-down


93. Shafi R, Afzal MN: Status of serum leptin levels in females with infertility. Saudi Med J; 2008 Oct;29(10):1419-22
MedlinePlus Health Information. consumer health - Female Infertility.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of serum leptin levels in females with infertility.
  • OBJECTIVE: To assess serum leptin levels in infertile females referred to a tertiary care hospital in Pakistan.
  • Serum leptin levels of 44 infertile females were compared with 44 age matched fertile female controls.
  • RESULTS: The results revealed that serum leptin levels were significantly raised in infertile women (69.7+/-40.2ng/ml) as compared to fertile controls (41.1+/-27.3ng/ml) with p=0.000.
  • Moreover, a strong positive correlation was found between BMI and leptin levels as leptin levels increased with increase in BMI.
  • Mean leptin levels in overweight women were significantly higher (81.4+/-32.4ng/ml) as compared to normal weight women (30.6+/-20.6ng/ml) with p=0.000.
  • However, further studies are required to determine the exact mechanism by which enhanced body mass and serum leptin levels lead to female infertility.
  • [MeSH-major] Infertility, Female / blood. Leptin / blood

  • Genetic Alliance. consumer health - infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18946565.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Leptin
  •  go-up   go-down


94. Wang PJ, Liu LW, Luo H, Xiao H, Cao H, Yu Y: [Serum leptin level in patients with obstructive sleep apnea-hypopnea syndrome]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2005 Apr;40(4):243-6
Genetic Alliance. consumer health - Sleep Apnea.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serum leptin level in patients with obstructive sleep apnea-hypopnea syndrome].
  • OBJECTIVE: To investigate the effect of uvulopalatopharyngoplasty on changes of serum leptin levels in patients with obstructive sleep apnea-hypopnea syndrome (OSAHS).
  • Pretreatment and post-uppp serum leptin concentrations in patients with OSAHS and in BMI-matched controls were measured by radioimmunoassay.
  • Correlations between leptin concentrations and AHI, BMI were analyzed.
  • RESULTS: The concentrations of leptin in patients with OSAHS were higher than that in controls (P < 0.05).
  • Mean levels (x+/-s) of leptin were (9.8+/-2.1) microg/L, (14.2+/-6.7) microg/L, and (19.3+/-7.9) microg/L in patients with severe, mediate and mild obstructive sleep apnea, respectively.
  • Serum leptin levels correlated positively with the degree of OSAHS as reflected by AHI (r = 0.
  • The leptin concentration of 51 responders after 6 months were significantly decreased (P < 0.01) than that of pre-operation.
  • However, the difference of leptin concentration between pre-operation and post operation was not significant in 9 nonresponders (P > 0.05).
  • CONCLUSIONS: There are higher leptin concentrations in patients with OSAHS, which are significantly correlated to the severity of disease.
  • Serum leptin levels in responders decreased significantly after uvulopalatopharyngoplasty.
  • OSAHS may influence the leptin system, resulting in increased serum leptin level.
  • [MeSH-major] Leptin / blood. Sleep Apnea, Obstructive / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008254.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


95. Bertazzoni P, Rabascio C, Gigli F, Calabrese L, Radice D, Calleri A, Gregato G, Negri M, Liptrott SJ, Bassi S, Nassi L, Sammassimo S, Laszlo D, Preda L, Pruneri G, Orlando L, Martinelli G: Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients. Leuk Lymphoma; 2010 Aug;51(8):1485-93
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients.
  • The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL).
  • Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m(2) on day 1 and cladribine 0.1 mg/kg subcutaneously on days 2-6.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578816.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Equilibrative Nucleoside Transporter 1; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / SLC29A1 protein, human; 0 / cif nucleoside transporter; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


96. Jose VJ, Mariappan P, George PV, Selvakumar, Selvakumar D: Serum leptin levels in acute myocardial infarction. Indian Heart J; 2005 Jan-Feb;57(1):39-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum leptin levels in acute myocardial infarction.
  • BACKGROUND: Several studies have shown an association of serum leptin levels with cardiovascular diseases.
  • The present study was undertaken to assess levels of serum leptin in patients presenting with acute ST segment elevation myocardial infarction.
  • The serum leptin levels in patients with myocardial infarction was 6.51 +/- 6.76 ng/ml versus 2.86 +/- 2.22 ng/ml in controls.
  • In the multivariate analysis the odds ratio for serum leptin with myocardial infarction was 1.45 with a 95% confidence interval of 1.2 to 1.8.
  • CONCLUSIONS: Our results suggest that serum leptin level is elevated in patients with acute ST segment elevation myocardial infarction.
  • [MeSH-major] Leptin / blood. Myocardial Infarction / blood

  • MedlinePlus Health Information. consumer health - Heart Attack.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852893.001).
  • [ISSN] 0019-4832
  • [Journal-full-title] Indian heart journal
  • [ISO-abbreviation] Indian Heart J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


97. Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, Lucas DM, Phan SC, Miller RA, Byrd JC: Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk Lymphoma; 2009 Dec;50(12):1977-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.
  • Chronic lymphocytic leukemia (CLL) cells are susceptible to oxidative stress.
  • A phase II trial administered MGd 5 mg/kg/day IV for 5 days every 3 weeks until disease progression to patients with previously treated CLL and small lymphocytic lymphoma.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Metalloporphyrins / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 17 / genetics. Drug Administration Schedule. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Immunoblotting. In Situ Hybridization, Fluorescence. Male. Middle Aged. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Treatment Outcome

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860624.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Metalloporphyrins; 6433A42F4F / motexafin gadolinium; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


98. Sriganeshan V, Blom TR, Weissmann DJ: A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+ immunophenotype and typical morphology. Arch Pathol Lab Med; 2008 Aug;132(8):1346-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of mantle cell lymphoma with an aberrant CD5-/CD10+ immunophenotype and typical morphology.
  • Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma with a poor prognosis that may be confused with less aggressive diseases, such as small lymphocytic lymphoma and follicular lymphoma.
  • In many cases immunophenotyping, particularly analysis of reactivity for CD5 and CD10, is an important adjunct to morphology that usually distinguishes MCL from follicular lymphoma; the former is CD5(+)/CD10(-), whereas follicular lymphoma is the reverse.
  • We report a case of MCL, initially diagnosed as follicular lymphoma, that at presentation expressed neither CD5 nor CD10.
  • Studies for a t(11;14) translocation and CYCLIN D1 protein expression, however, permitted a revised diagnosis of MCL.
  • [MeSH-major] Antigens, CD5 / analysis. Head and Neck Neoplasms / immunology. Head and Neck Neoplasms / pathology. Immunophenotyping. Lymphoma, Mantle-Cell / immunology. Lymphoma, Mantle-Cell / pathology. Neprilysin / analysis
  • [MeSH-minor] Aged. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 14. Cyclin D1 / analysis. Diagnosis, Differential. Female. Humans. Translocation, Genetic

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18684040.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5; 136601-57-5 / Cyclin D1; EC 3.4.24.11 / Neprilysin
  • [Number-of-references] 15
  •  go-up   go-down


99. Gol M, Ozsener S, Sendag F, Uretmen S, Oztekin K, Tanyalcin T, Bilgin O: Does tibolone affect serum leptin levels and body weight in postmenopausal women? Arch Gynecol Obstet; 2005 Jul;272(2):127-30
MedlinePlus Health Information. consumer health - Body Weight.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does tibolone affect serum leptin levels and body weight in postmenopausal women?
  • OBJECTIVES: Leptin has a significant role in body weight regulation and energy balance.
  • We examined the effect of tibolone on the body weight and serum leptin levels in postmenopausal women.
  • Absolute and body mass index (BMI)-corrected serum leptin concentrations and BMI values were measured at baseline, after 3 months, and after 6 months of the tibolone therapy.
  • RESULTS: Tibolone did not affect absolute and BMI-corrected serum leptin levels, and BMI values during the treatment.
  • A significant linear correlation between BMI values and serum leptin levels was observed (p<0.05, r=0.67).
  • CONCLUSIONS: Tibolone seems not to affect serum leptin levels, body weight and BMI values of postmenopausal women.
  • There is a significant correlation between serum leptin levels and BMI values.
  • [MeSH-major] Body Weight / drug effects. Estrogen Receptor Modulators / pharmacology. Leptin / blood. Norpregnenes / pharmacology. Postmenopause / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15517326.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Estrogen Receptor Modulators; 0 / Leptin; 0 / Norpregnenes; FF9X0205V2 / tibolone
  •  go-up   go-down


100. Yan GT, Hao XH, Xue H, Lin J, Zhang K, Wang LH: [Changes in serum leptin levels in patients with surgically induced stress responses]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2006 Mar;18(3):172-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in serum leptin levels in patients with surgically induced stress responses].
  • OBJECTIVE: To explore the effect of operative trauma induced stress responses on serum leptin levels.
  • METHODS: Serum samples of patients who had undergone resection of hepatic tumors or cholecystectomy were collected, and highly sensitive radioimmunoassay and enzyme-linked immunoadsorbent assay (ELISA) were used to determine serum levels of leptin, granulocyte-clone stimulating factor (G-CSF), C-reactive protein (CRP) and adrenocorticotropin hormone (ACTH) in the blood of these patients.
  • RESULTS: Compared with self-control before operation, serum leptin levels decreased slightly right after an abdominal operation (T0), it reached the highest level 1 day after operation (T1), and began to decrease from 2 days (T2) to 4 days after operation (T4), but the level was still higher than that before operation.
  • Serum leptin levels of patients undergoing laparoscopic operation showed no significant difference when compared with that of laparotomy patients.
  • G-SF levels decreased significantly after operation in both groups, and didn't recover to the levels before operation from T1 to T4.
  • CRP levels slightly decreased in both groups at T0, but increased significantly higher than the levels before operation from T1 to T4.
  • ACTH levels of decreased significantly in laparotomy patients from T0 to T1, and began to recover on T2, while that of laparoscopic operation patients showed no significant difference before and after operation.
  • CONCLUSION: Serum leptin levels of patients increase significantly and constantly subsequent to operative trauma induced stress responses, but this change has no correlation with that of CRP, G-SF and ACTH.
  • [MeSH-major] Leptin / blood. Surgical Procedures, Operative

  • MedlinePlus Health Information. consumer health - Surgery.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524513.001).
  • [ISSN] 1003-0603
  • [Journal-full-title] Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue
  • [ISO-abbreviation] Zhongguo Wei Zhong Bing Ji Jiu Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Leptin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 9002-60-2 / Adrenocorticotropic Hormone; 9007-41-4 / C-Reactive Protein
  •  go-up   go-down






Advertisement